Introduction {#s1}
============

Pancreatic ductal adenocarcinoma (PDA) is projected to be the second leading cause of cancer deaths in the U.S. by 2020 ([@bib58]). The exceeding lethality of PDA is attributed to a complex of qualities frequent to the disease including early and aggressive metastasis and limited responsiveness to current standards of care. While both aspects are in-and-of-themselves multifaceted and can be partially attributed to factors such as the tumor microenvironment ([@bib50]; [@bib57]; [@bib71]) and the mutational profile of the tumor cells ([@bib74]), cancer stem cells (CSCs) have also been identified to contribute to promoting early metastasis and resistance to therapeutics ([@bib18]; [@bib31]).

CSCs, which were originally identified in leukemias ([@bib7]; [@bib16]), have been identified in a number of solid tumors including glioblastoma ([@bib66]), pancreas ([@bib30]; [@bib18]) and colon ([@bib47]). In these cases, CSCs have been characterized by the ability to establish disease in immunocompromised mice, to resist chemotherapeutics, the capability of both self-renewal and differentiation into the full complement of heterogeneous neoplastic cells that comprise the tumor, and the propensity to metastasize. In each case, CSCs are distinguished from other tumor cell types by the expression of various, sometimes divergent cell surface markers. Our lab was the first to identify pancreatic cancer stem cells (PCSCs), which were found to express the markers EPCAM (ESA), CD44, and CD24 ([@bib30]). In addition to these markers, CD133 ([@bib18]), CXCR4 ([@bib18]), c-MET ([@bib31]), aldehyde dehydrogenase 1 (ALDH1) ([@bib23]), and autofluorescence ([@bib41]) have all been proposed markers of PCSCs. In all cases, the identified cells are characterized by being able to form spheres of cells (tumorspheres) under non-adherent, serum-free conditions, as well as an increased ability to form tumors in mice compared to bulk tumor cells. While a number of markers have been identified for PCSCs, relatively little is known about the transcriptional platforms that govern their function and set them apart from the majority of bulk PDA cells. Transcriptional regulators such as NOTCH ([@bib72]; [@bib1]), BMI1 ([@bib56]), and SOX2 ([@bib19]) have been demonstrated to play roles in PCSCs, although these proteins are also critical for normal stem cell function in many tissues.

In this study, we sought to better understand the biological heterogeneity of PCSCs and their bulk cell counterparts in an effort to identify novel regulators of PCSCs in the context of low-passage, primary patient-derived PDA cells. Using microarray analysis and comparing primary PDA cell subpopulations with different levels tumorigenic potential and stem-cell-like function, we identified hepatocyte nuclear factor 1-alpha (HNF1A), an endoderm-restricted transcription factor, as a key regulator of the PCSC state. Supporting this hypothesis, depletion of HNF1A resulted in a loss of PCSC marker expression and functionality both in vitro and in vivo. Additionally, ectopic expression of HNF1A augmented PCSC properties in PDA cells and enhanced growth and anchorage-independence in normal pancreatic cell lines. Mechanistically, we found that HNF1A directly regulates transcription of the stem cell transcription factor *POU5F1*/*OCT4*, which is necessary for stemness in PCSCs. Based on these data, we postulate a novel pro-oncogenic function for HNF1A through its maintenance of the pancreatic cancer stem cell properties.

Results {#s2}
=======

An HNF1A gene signature dominates a PCSC gene signature {#s2-1}
-------------------------------------------------------

A transcriptional profile of PCSCs has yet to be established, and we hypothesized that such a profile would contain key regulators of the PCSC state. To pursue this hypothesis, we utilized a series of low-passage, patient-derived PDA cell lines to isolate PCSC-enriching and non-enriching subpopulations for comparative analysis. Using two of our previously described PCSC surface markers, CD44 and EPCAM ([@bib30]), we found that low-passage PDA cells generally formed three subpopulations (abbreviated P herein) based on surface staining: CD44^High^/EPCAM^Low^ (P1), CD44^High^/EPCAM^High^ (P2), or CD44^Low^/EPCAM^High^ (P3) ([Figure 1A](#fig1){ref-type="fig"}). Similar expression patterns were observed in 10 primary tumor samples (data not shown). Additionally, a CD44^Low^/EPCAM^Low^ subpopulation was observed in five samples (data not shown), consistent with our previous data ([@bib30]). Using previously described measures of PCSC function ([@bib30]; [@bib31]), including co-expression of the PCSC marker CD24 ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}), the abilities for isolated subpopulations to reestablish heterogeneous CD44 and EPCAM surface expression ([Figure 1B](#fig1){ref-type="fig"}), to form tumorspheres under non-adherent/serum-free culture conditions ([Figure 1C,D](#fig1){ref-type="fig"}), and to initiate tumors in immune-deficient mice ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), we found that P2 cells showed greater enrichment for cells with PCSC properties than their P1 and P3 counterparts.

![HNF1A-signature dominates pancreatic CSCs.\
(**A**) Flow cytometry analysis of CD44 and EPCAM surface expression of three primary PDA samples. (**B**) CD44^High^/EPCAM^Low^ (P1), CD44^High^/EPCAM^High^ (P2) and CD44^Low^/EPCAM^High^ (P3) NY8 cells were isolated by FACS and grown in culture for 17 days, followed by flow cytometry for analysis for CD44 and EPCAM expression. (**C, D**) Isolated subpopulations were grown in tumorsphere media on non-adherent plates (500 cells/well) for 6 days. Representative images of resultant tumorspheres (100X magnification) are shown in (**C**), while quantitation of spheres (n = 3) is shown in (**D**). Statistical difference was determined by one-way ANOVA with Tukey's multiple comparisons test. (**E**) Heat map representing relative fold differences in qRT-PCR expression of 50 cancer stem-cell-enriched genes in NY8 and NY15 cells. Per-gene values are relative to P1 or P3, whichever is higher. Gene names in red text indicate predicted HNF1A targets and asterisks (\*) indicate known HNF1A targets. P1: CD44^High^/EPCAM^Low^, P2: CD44^High^/EPCAM^High^, P3: CD44^Low^/EPCAM^High^. For all genes, expression levels were normalized to an *ACTB* mRNA control, n = 3. Only genes with a significant (p\<0.05) increase in P2 over both P1 and P3 subpopulations are shown, with statistical difference determined by one-way ANOVA with Tukey's multiple comparisons test. (**F**) qRT-PCR analysis of *HNF1A* mRNA expression, normalized to an *ACTB* mRNA control, from different primary PDA subpopulations (n = 3). Statistical difference was determined by one-way ANOVA with Tukey's multiple comparisons test. Related data can be found in [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}.\
10.7554/eLife.33947.006Figure 1---source data 1.Quantitation of tumorspheres, P2 subpopulation-enriched transcripts, and HNF1A mRNA.\
10.7554/eLife.33947.007Figure 1---source data 2.Quantitation of GFP expression in adherent cells and tumorspheres.](elife-33947-fig1){#fig1}

Using two primary PDA lines (NY8 and NY15), P1, P2, and P3 PDA cells were sorted by flow cytometry, prepped immediately for mRNA, and analyzed by Affymetrix GeneChip microarray and validated by quantitative RT-PCR. We found that P2 cells from both lines exhibited a signature of 50 genes that was upregulated (\>1.5 fold) relative to both P1 and P3 cell counterparts ([Figure 1E](#fig1){ref-type="fig"}). To further refine this gene cohort, we utilized oPOSSUM ([@bib27]), a web-based system to detect overrepresented transcription-factor-binding sites in gene sets. Interestingly, HNF1A, a P2 cohort gene itself ([Figure 1E,F](#fig1){ref-type="fig"}), had predicted binding sites in the ±5000 regions (from start of transcription) of 17/50 of the enriched genes, and due to its stringent consensus sequence (DGTTAATNATTAAC) was the most highly ranked common transcription factor by Z-score (17.895). Of these 50 genes, HNF1A is known to positively regulate cohort genes *HNF4A* ([@bib6]), *NR5A2* ([@bib43]), *CDH17* ([@bib77]), *IGFBP1* ([@bib2]; [@bib55]), and *DPP4* ([@bib17]). Interestingly, genome-wide association (GWA) studies have recently identified certain single nucleotide polymorphisms (SNPs) in the HNF1A locus as risk factors for developing PDA ([@bib54]; [@bib32]; [@bib73]), although the mechanism by which these SNPs exert their influence is currently unknown. Similarly, SNPs in the HNF1A target NR5A2 are also associated with the development of PDA ([@bib53]; [@bib59]), further implicating a role for the HNF1A-transcriptional network in PDA. To further support the enrichment of HNF1A in PCSCs, sorted cells were western blotted for HNF1A and HNF1A-target proteins, CDH17 and DPP4. These proteins were found to be elevated in P2 cell lysates compared to other subpopulations ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), in agreement with their transcript levels. CSCs are enriched in cancer cell populations grown under low-attachment tumorsphere (S) conditions compared to cells grown in adherent (A) conditions. In keeping with this observation, we found protein levels of HNF1A and CDH17 elevated in multiple PDA lines cultured under tumorsphere conditions ([Figure 1---figure supplement 2A and C](#fig1s2){ref-type="fig"}). Using a GFP-based reporter driven by eight tandem copies of the HNF1A consensus sequence GGTTAATGATTAACC ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), we found GFP expression was elevated in NY5, NY8, and NY15 cells grown under tumorsphere (S) compared to adherent conditions (A) ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}). This construct showed excellent dependence on HNF1A expression as targeting HNF1A with an HNF1A-specific siRNA ablated expression of both the ectopic GFP and endogenous CDH17 ([Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}). Lastly, we found the frequency of GFP-positive cells increased in cells grown in suspension ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}), with GFP expression being highest in the P2 subpopulation of NY15 cells ([Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}). Based on our gene expression and tumorsphere data, we hypothesized that HNF1A is a central regulator of CSC function.

HNF1A is a critical regulator of CSC properties in PDA cells {#s2-2}
------------------------------------------------------------

Consistent with our hypothesis that HNF1A may be an integral component of PDA biology we observed higher levels of HNF1A protein and transcripts in PDA cells compared to non-transformed immortalized pancreatic cell lines HPNE (N) and HPDE (D) ([Figure 2A](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Immunostaining of a PDA tissue microarray showed HNF1A expression to be significantly elevated (p\<0.0001) in PDA neoplastic ducts (n = 41) compared to normal pancreatic ducts (n = 18) ([Figure 2---figure supplement 1B,C](#fig2s1){ref-type="fig"}). To examine the role of HNF1A in PDA cells, we depleted the protein with two distinct siRNAs ([Figure 2B](#fig2){ref-type="fig"}). Knockdown of HNF1A resulted in reduced cell numbers in multiple primary PDA lines ([Figure 2C](#fig2){ref-type="fig"}). To determine whether the apparent loss in cell number was due to apoptotic cell death, we performed annexin V/DAPI staining on control and HNF1A-depleted NY5, NY8, and NY15 cells. In all cases, knockdown of HNF1A resulted in a significant (p\<0.05) increase in apoptotic cells, while not affecting necrotic cell numbers ([Figure 2D](#fig2){ref-type="fig"}, data not shown). Furthermore, increased cleavage of caspases 3, 6, 7, and 9 was observed in cells depleted of HNF1A ([Figure 2E](#fig2){ref-type="fig"}), indicating apoptotic cell death. These data indicate that HNF1A is important for PDA cell growth and survival.

![Knockdown of HNF1A in primary PDA cells inhibits growth in vitro.\
(**A**) Western blot analysis of HNF1A expression in a panel of primary PDA lines compared to immortalized pancreatic ductal cell line HPNE and HPDE. Quantitation of HNF1A protein is indicated below the respective blots. (**B**) Western blot of NY5, NY8, and NY15 cells transfected with non-targeting (Ctl) or HNF1A-targeting siRNA for 3 days, showing effective depletion of HNF1A protein by RNAi. Quantitation of HNF1A protein is indicated below the respective blots. (**C**) 1.5 × 10^5^ PDA cells were transfected with control (Ctl) or HNF1A-targeting siRNA (Day 1). Cells were collected and manually counted 3 and 6 days after transfection (n = 3). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. Red and green p values indicate Ctl vs. HNF1A\#1 or \#2, respectively. (**D**) Annexin V staining was performed on NY5, NY8, and NY15 cells transfected with control (Ctl) or HNF1A-targeting siRNA (**H1, H2**) for 3 days. The amount of apoptotic (annexin V+) cells are quantitated (n = 4). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test, with p values relative to the control siRNA group indicated. (**E**) Western blot analysis of cleaved caspases in NY8 and NY15 cells following HNF1A-knockdown (3 days). Actin serves as a loading control. Quantitation of proteins is indicated below the respective blots. Related data can be found in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.\
10.7554/eLife.33947.010Figure 2---source data 1.Quantitation of PDA cell growth and apoptosis following HNF1A knockdown.\
10.7554/eLife.33947.011Figure 2---source data 2.Quantitative PCR analysis of HNF1A mRNA in PDA cells and histology score of HNF1A staining in normal and neoplastic ducts..](elife-33947-fig2){#fig2}

Next, we pursued whether depletion of HNF1A impacted PDA subpopulation distribution. Consistent with a central role in maintaining heterogeneous EPCAM and CD44 expression, we observed a change in P2 in all cell lines ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) with a concomitant increase in the P3 population ([Figure 3---figure supplement 1A,C](#fig3s1){ref-type="fig"}). NY8 cells showed a loss in the P1 population as well ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). Collectively, these results support a role for HNF1A in maintaining cellular heterogeneity, with the most dramatic change being the consistent loss of the PCSC population. In addition to changes in CD44 and EPCAM surface expression, we also observed a marked decrease in CD24 surface expression ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}) and mRNA levels (data not shown) in multiple PDA lines; suggesting that loss of HNF1A depletes the CSC compartment. To assess functional consequences of HNF1A-depletion on the PCSC compartment, cells (NY5, NY8, NY15) expressing HNF1A shRNAs were grown under tumorsphere-promoting conditions. These shRNAs effectively depleted HNF1A as well as CDH17 ([Figure 3C](#fig3){ref-type="fig"}), indicating downstream signaling inhibition. Consistent with a role in PCSC function, HNF1A knockdown showed a marked reduction in tumorsphere formation (p\<0.05) ([Figure 3D,E](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).

![Knockdown of HNF1A depletes CSC numbers.\
(**A**) Multiple PDA cells were transfected with HNF1A-targeting siRNA or non-targeting control siRNA for 6 days. Surface expression of CD44 and EPCAM was measured by flow cytometry, and the percentage of CD44^High^/EPCAM^High^ (P2) cells are represented (mean ± SEM, n = 3). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. (**B**) Quantitation of CD24 +cells in multiple primary PDA cells following HNF1A knockdown for 6 days, n = 4. Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. (**C**) NY5, NY8, and NY15 cells expressing LacZ2.1 (**L**) or two distinct HNF1A-targeting shRNAs (H1 and H2) were lysed and western blotted for HNF1A, CDH17, and Actin, showing effective knockdown of HNF1A and downstream signaling (CDH17). Quantitation of proteins is indicated below the respective blots. (**D, E**) NY5, NY8, and NY15 cells expressing LacZ2.1 or HNF1A-targeting shRNAs were grown in tumorsphere media on non-adherent plates (1500 cells/well). The number of tumorspheres formed after 6 days were counted (n = 3). Representative images of spheres (100X magnification) are shown in (**F**) and in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, with quantitation in (**E**). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. Related data can be found in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.\
10.7554/eLife.33947.014Figure 3---source data 1.Quantitation of the P2 subpopulation, CD24 expression, and tumorsphere formation following HNF1A knockdown.](elife-33947-fig3){#fig3}

HNF1A exhibits oncogenic properties in pancreatic cells {#s2-3}
-------------------------------------------------------

We next sought to determine whether CSC properties could be augmented by ectopic expression of HNF1A in PDA cells. For these studies, we selected PDA lines with high (NY15), medium (NY8), and low (NY53) expression of HNF1A ([Figure 2A](#fig2){ref-type="fig"}) to determine if additional HNF1A expression could bolster PCSC properties under different cellular contexts. Using doxycycline-inducible expression of HNF1A ([Figure 4A,B](#fig4){ref-type="fig"}), we noted increased expression of CD24, CD44, and EPCAM in multiple primary PDA lines ([Figure 4B--D](#fig4){ref-type="fig"}, data not shown), indicating that ectopic HNF1A can increase PCSC marker expression in PDA cells. Additionally, we found that HNF1A-expressing cells formed \~2.5 fold more tumorspheres than their counterparts ([Figure 4E](#fig4){ref-type="fig"}) in all PDA cells tested. Taken together, these data indicate that ectopic HNF1A can promote PCSC properties, even in the presence of higher endogenous expression (i.e. NY15).

![Overexpression of HNF1A promotes CSC properties in PDA cells and normal pancreatic cell lines.\
(**A**) NY15 and NY53 cells Western blotted for HNF1A and control gene induction following 48 hr ± doxycycline (Dox). Quantitation of proteins is indicated below the respective blots. (**B**) NY8 cells were treated 48 hr ± Dox to induce ectopic HNF1A. Lysates were western blotted for HNF1A, Actin, and PCSC markers EPCAM and CD44. Quantitation of proteins is indicated below the respective blots. (**C**) Representative surface expression of CD24 and EPCAM on NY15 cells expressing GFP or HNF1A. (**D**) Quantitation of CD24 +NY15 GFP and HNF1A cells and NY8 and NY53 LacZ and HNF1A cells by flow cytometry (n = 3). Statistical difference was determined by one-way ANOVA with Tukey's multiple comparisons test. (**E**) NY15 GFP and HNF1A, NY8 and NY53 LacZ and HNF1A cells were grown under sphere-forming conditions ± Dox. The number of tumorspheres formed after 7 days were quantitated (n = 4). Statistical difference was determined by one-way ANOVA with Tukey's multiple comparisons test. Representative images (100X magnification) of spheres are shown in the upper panels. (**F, G**) HPNE LacZ and HNF1A cells were plated at 200 cells/6 cm dish and treated ±Dox for 2 weeks, fixed, and stained with crystal violet (**F**). (**G**) Resultant colonies were quantitated (n = 3). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. (**H, I**) HPDE cells expressing inducible LacZ, LacZ with KRAS^G12D^, HNF1A, or HNF1A with KRAS^G12D^ were embedded in soft agar + Dox and monitored for signs of anchorage-independent growth for 21 days. (**H**) Representative images of resultant colonies (100X magnification) and (**I**) quantitation of colonies after 21 days (n = 3). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. Related data can be found in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.\
10.7554/eLife.33947.017Figure 4---source data 1.Quantitation of CD24 expression and tumorsphere formation in PDA cells with HNF1A overexpression, and quantitation of colony formation in HPNE and HPDE cells expressing HNF1A and oncogenic KRAS.\
10.7554/eLife.33947.018Figure 4---source data 2.Quantitation of CD44+/CD24+ HPDE and HPNE cells overexpressing HNF1A.](elife-33947-fig4){#fig4}

We next examined the effects of ectopic HNF1A expression in the non-tumorigenic pancreatic ductal cell lines HPDE and HPNE, which were devoid of endogenous HNF1A expression ([Figure 2A](#fig2){ref-type="fig"}). Doxycycline-inducible ectopic expression of HNF1A alone or in concert with ectopic KRAS^G12D^ was readily achieved in HPDE cells ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Consistent with previous reports, KRAS^G12D^-induced phosphorylation of both ERK1/2 and AKT in HPDE cells. Similar effects were seen in HPNE cells constitutively expressing HNF1A and KRAS^G12D^ alone or in combination ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). We then tested the impact the of HNF1A and/or KRAS^G12D^ expression, either alone or in combination, on HPDE cell growth. Under normal growth conditions with serum, (LacZ) HPDE cells grew to confluency but did not form colonies, presumably due to contact-inhibition ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Expression of KRAS^G12D^, however, resulted in colony formation, indicating a bypass of contact inhibition. HNF1A alone resulted in significantly increased colony formation, which was further enhanced by the additional expression of KRAS^G12D^. Similar effects were seen in HPNE cells (data not shown). In clonogenicity assays, HNF1A-expressing HPNE cells formed similar numbers of colonies to control and KRAS^G12D^-expressing cells ([Figure 4F,G](#fig4){ref-type="fig"}); however, HNF1A alone promoted enhanced colony size. HPDE cells failed to form colonies at clonal densities in the presence of serum. In addition to foci formation, anchorage-independent growth can indicate cellular transformation in vitro. When suspended in soft agar, control HPDE cells failed to grow over a 21-day period ([Figure 4H,I](#fig4){ref-type="fig"}). The addition of KRAS^G12D^ alone did not significantly promote colony formation, consistent with its relatively weak transforming ability in HPDE cells. Interestingly, HNF1A alone resulted in numerous small colonies which in turn synergized with the expression of KRAS^G12D^ in the form of numerous large colonies. Neither HNF1A nor KRAS^G12D^ alone resulted in anchorage-independent growth in HPNE cells (data not shown). Lastly, we examined the effects of both transgenes on PCSC marker expression. Expression of HNF1A increased expression of EPCAM, CD44, and CD24 in HPDE cells ([Figure 4---figure supplement 1A,C](#fig4s1){ref-type="fig"}). Control HPNE cells lacked expression of both EPCAM and CD24, but expressed high levels of CD44. Expression of HNF1A was able to increase CD44 surface expression, while not changing EPCAM status ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}, data not shown). Remarkably, CD24 was potently induced upon HNF1A expression, with nearly 83% of HPNE cells expressing CD24 compared to 0.5% of LacZ-expressing control cells. These data would suggest that HNF1A possesses properties of an oncogene capable of cooperation with oncogenic KRAS.

HNF1A is required for tumor growth and cancer stem cells properties in vivo {#s2-4}
---------------------------------------------------------------------------

To determine whether HNF1A was necessary for tumorigenesis, we implanted two HNF1A-high primary lines (NY5 and NY15) expressing control or two HNF1A-targeting shRNAs orthotopically in the pancreas of NOD/SCID mice. HNF1A-depleted cells showed significantly reduced tumor growth compared to their control cohorts (p\<0.05), ([Figure 5A,B](#fig5){ref-type="fig"}). Similar results were observed with HNF1A knockdown in subcutaneous xenografts of NY5 and NY15 cells ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). To determine whether inhibition of tumor growth was due to effects on the PCSC compartment, NY5 tumors were dissociated and analyzed by flow cytometry. Consistent with our in vitro findings, the EPCAM+/CD44+/CD24 +cell population was significantly reduced in HNF1A-depleted tumors (p\<0.05) ([Figure 5D,E](#fig5){ref-type="fig"}). Importantly, western blot analysis of resultant tumor lysates confirmed that shRNAs remained effective at depleting HNF1A during the course of the experiment ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}).

![Knockdown of HNF1A impairs tumor growth and depletes CSCs in vivo.\
(**A, B**) 10,000 firefly luciferase-labeled NY5 and NY15 cells expressing control or HNF1A shRNAs were implanted orthotopically into the pancreata of NOD/SCID mice and monitored by IVIS imaging for 6 weeks (10 mice per group). Representative luminescence image of tumors prior to sacrifice is shown (**A**). Final tumor volumes determined during necropsy are quantitated in (**B**). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. (**C**) 10^3^ control or HNF1A-depleted NY5 cells were implanted subcutaneously in NOD/SCID mice (10 mice per shRNA/bilateral injections) for 11 weeks. Tumors were measured by caliper to determine tumor growth (C, upper panel). Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. Red and orange p values indicate LacZ2.1 vs. HNF1A\#1 or \#2, respectively. 'n.d.' indicates that tumors were not detected. Representative tumors excised at sacrifice are shown (C, lower panel). (**D, E**) NY5 tumors from (**A**) were dissociated and stained for EPCAM, CD44, and CD24. Representative flow cytometry plots for recovered tumor cells are shown in (**D**), where the R22 gate denotes EPCAM^High^/CD44^High^ cells, and CD24 +cells are donated in red. Quantitation of EPCAM+/CD44+/CD24 +cells is shown in (**E**), n = 6 tumors each for shRNA. Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. Related data can be found in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.\
10.7554/eLife.33947.021Figure 5---source data 1.Quantitation of orthotopic and subcutaneous xenograft tumor volumes, and quantitation of PCSCs following HNF1A knockdown.\
10.7554/eLife.33947.022Figure 5---source data 2.Quantitation of subcutaneous xenograft tumor volumes following HNF1A knockdown.](elife-33947-fig5){#fig5}

HNF1A regulates stemness through POU5F1/OCT4 expression {#s2-5}
-------------------------------------------------------

As a direct relationship between HNF1A and stem cell function has not been reported, we examined mRNA expression of central stemness regulators *MYC*, *SOX2*, *KLF4*, *NANOG*, and *POU5F1*/*OCT4* in HNF1A-depleted cells. Of these transcription factors, only *POU5F1/OCT4* mRNA showed consistent downregulation in multiple PDA cell lines in response to HNF1A knockdown ([Figure 6A](#fig6){ref-type="fig"}, data not shown). Similarly, we found that *POU5F1/OCT4* mRNA was upregulated in response to overexpression of HNF1A in both PDA cells and HPDE cells ([Figure 6B](#fig6){ref-type="fig"}), indicating regulation of *POU5F1/OCT4* expression by HNF1A in pancreatic-lineage cells. To determine whether *POU5F1/OCT4* mRNA was correlated with HNF1A expression, qRT-PCR was performed in 22 primary PDA lines as well as HPNE and HPDE cells. The Pearson correlation coefficient of *POU5F1/OCT4* mRNA was found to be significantly correlated (p=0.0094) with *HNF1A* mRNA levels ([Figure 6C](#fig6){ref-type="fig"}). Additionally, *POU5F1/OCT4* and *HNF1A* mRNA levels were correlated (Pearson's r = 0.406, p=8.9×10^−8^) in patient tumors samples from The Cancer Genome Atlas (TCGA) dataset for PDA (PAAD cohort, data not shown), further supporting relationship between the two genes. Despite a strong association between *POU5F1/OCT4* and *HNF1A* mRNA levels, we did not observe a significant association between *POU5F1/OCT4* mRNA and any of the PDA subpopulations, indicating that factors other than HNF1A modulate the levels of *POU5F1/OCT4* mRNA in different PDA subpopulations (data not shown).

![HNF1A regulates stemness through *POU5F1/OCT4* regulation.\
(**A**) qRT-PCR analysis of *POU5F1/OCT4* mRNA in NY5, NY8 and NY15 cells expressing control (LacZ2.1) or HNF1A shRNAs. *ACTB* was used as an internal control, n = 3. Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. (**B**) LacZ or HNF1A was induced in NY8, NY15 or HPDE cells with doxycycline for 6 days. Levels of *POU5F1/OCT4* mRNA were measured by qRT-PCR with *ACTB* as an internal control, n = 3. Statistical difference was determined by unpaired t test with Welch's correction. (**C**) Pearson correlation coefficient of *POU5F1/OCT4* and *HNF1A* mRNA levels from NY PDA cells (n = 22, red) relative to HPNE and HPDE (blue) cells. (**D**) Western blot of OCT4A and HNF1A protein in NY5 and NY8 cells transfected with POU5F1/OCT4 (labeled OCT4) or HNF1A SMARTpool siRNA for 3 days. Quantitation of proteins is indicated below the respective blots. (**E**) NY5 and NY8 cells were transfected with HNF1A or POU5F1/OCT4 SMARTpool siRNA for 3 days and then grown in tumorsphere media on non-adherent plates (1500 cells/well). Spheres were quantitated 7 days later, n = 3. Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. (**F--H**) NY15 cells were transfected with POU5F1/OCT4 SMARTpool (SP) siRNA or individual sequences for 3 days and either harvested to assess OCT4A knockdown by Western blot (**F**) or grown in tumorsphere media on non-adherent plates (1500 cells/well) (**G**). Spheres were quantitated 7 days later, n = 3. Statistical difference was determined by one-way ANOVA with Dunnett's multiple comparisons test. Representative spheres are shown in (**H**). (**I**) NY8 and NY15 cells transduced with OCT4A (labeled OCT4) or empty vector control (EV) were transiently transfected with control (Ctl) or HNF1A-targeting siRNA for 72 hr, and then grown in tumorsphere media on non-adherent plates (1500 cells/well). Spheres were quantitated 7 days later, n = 3. Statistical difference was determined by one-way ANOVA with Tukey's multiple comparisons test. Related data can be found in [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}.\
10.7554/eLife.33947.026Figure 6---source data 1.Quantitation of OCT4/POU5F1 mRNA following HNF1A knockdown and overexpression; relative HNF1A and OCT4/POU5F1 mRNA expressions in PDA cells; quantitation of tumorspheres following OCT4/POU5F1 knockdown; and quantitation of tumorsphere formation following OCT4A rescue.\
10.7554/eLife.33947.027Figure 6---source data 2.Quantitation of ChIP, CLuc activity, annexin V staining, PI staining, and tumorsphere formation.](elife-33947-fig6){#fig6}

Previously published HNF1A chromatin immunoprecipitation sequencing (ChIP-seq) data performed in HepG2 cells by The Encyclopedia of DNA Elements (ENCODE) project ([@bib10]) identified a region of enrichment of HNF1A upstream of the POU5F1/PSORS1C3 gene loci proximal to recently identified retrotransposon long terminal repeat (LTR)-rich region that can serve as a promoter for both genes ([@bib37]). Additionally, enrichment of this LTR region by TATA-binding protein (TBP) and acetylated lysine 27 histone H3 supports the involvement of this region in the transcription of *POU5F1/OCT4*. Interestingly, this LTR promoter region contains three consensus half-sites for HNF1A ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). To test whether HNF1A binds directly to these half-sites, ChIP-PCR was performed in NY5, NY8, and NY15 cells. Consistent with the ENCODE data we observed significant enrichment of two half-sites in NY5 and all three half-sites in NY8 and NY15 by HNF1A. By contrast, the canonical distal enhancer of POU5F1/OCT4 ([@bib75]), located 14-kbp downstream of the LTR promoter, and HNF1A non-target gene MYOD showed no significant enrichment by HNF1A ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}), demonstrating the specificity of enrichment observed. To validate the LTR promoter region as an HNF1A-responsive promoter region, a reporter construct was generated encompassing the three putative HNF1A half-sites ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Co-transfection of 293FT cells (which lack endogenous HNF1A) with the LTR reporter and an HNF1A-expression plasmid resulted in a 4.5-fold induction of Cypridina luciferase expression over LacZ-expression plasmid co-transfected cells ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). Additionally, neither the cloning vector nor the canonical downstream promoter region of POU5F1/OCT4 showed responsiveness to HNF1A expression, supporting the POU5F1/OCT4 LTR promoter as the HNF1A-responsive promoter for the gene.

POU5F1/OCT4 has previously been shown to be elevated in PCSCs ([@bib41]; [@bib36]), although a functional role for the protein has not been demonstrated in this context. To determine if POU5F1/OCT4 regulation was a key event in HNF1A-dependent stemness, we targeted POU5F1/OCT4 with multiple siRNAs, either in combination or as single sequences. Depletion of POU5F1/OCT4 resulted in a pronounced inhibition of tumorsphere formation, comparable to HNF1A knockdown ([Figure 6D--H](#fig6){ref-type="fig"}). To determine whether changes in apoptosis or cell cycle were responsible for the loss of tumorsphere formation in response to POU5F1/OCT4 knockdown, we performed annexin V/DAPI staining and propidium iodide staining in NY8 cells following transfection with POU5F1/OCT4 siRNA. Consistent with its role as a regulator of stemness in normal and cancer stem cells ([@bib49]; [@bib67]; [@bib34]; [@bib26]; [@bib45]), we did not observe changes in either apoptosis or cell cycle in response to POU5F1/OCT4 knockdown ([Figure 6---figure supplement 2A,B](#fig6s2){ref-type="fig"}). Importantly, knockdown of either HNF1A or POU5F1/OCT4 had comparable effects on the protein levels of OCT4A ([Figure 6D](#fig6){ref-type="fig"}), the isoform responsible for imparting stemness ([@bib28]). To determine whether expression of OCT4A was sufficient to rescue stemness of PDA cells depleted of HNF1A, NY8, and NY15 cells were transduced with OCT4A-expressing lentiviruses or vector controls and transfected with HNF1A siRNA. Consistent with our previous results, loss of HNF1A impaired tumorsphere formation in both lines expressing the vector control, however, this effect was rescued by the expression of OCT4A ([Figure 6I](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2C,D](#fig6s2){ref-type="fig"}). These data indicate that HNF1A mediates stemness of PCSCs through direct transcriptional regulation of *POU5F1/OCT4*.

HNF1A targets associated with poor survival in PDA patients {#s2-6}
-----------------------------------------------------------

Lastly, we sought to gain insight into the transcriptional activity and genomic binding of HNF1A in PDA and determine whether its targets held prognostic information similar to other signatures in PDA ([@bib3]; [@bib9]). In order to identify transcriptional targets of HNF1A, we performed Bru-seq with control and HNF1A-depleted NY8 and NY15 cells (two replicates each of control shRNA and 2 HNF1A-targeting shRNAs per cell line). Bru-seq is a variation of RNA-seq which measures changes in nascent RNA levels (*bona fide* transcription rate) as opposed to steady-state mRNA changes measured by conventional RNA-seq and microarray ([@bib52]). Differentially expressed genes were defined by adjusted p value\<0.1 for at least one HNF1A-targeting shRNA and a mean expression level across samples (in RPKM) greater than 0.25. Of these differentially expressed genes, 243 HNF1A upregulated and 46 HNF1A downregulated were found to be in common between NY8 and NY15 ([Figure 7A](#fig7){ref-type="fig"}).

![HNF1A regulates a transcriptional program associated with poor survival in PDA.\
(**A**) Venn diagrams illustrating overlapping genes with altered transcription (Bru-seq) following HNF1A knockdown in NY8 and NY15 cells. 'HNF1A upregulated' genes denote genes that were downregulated by HNF1A shRNAs, while 'HNF1A downregulated' genes were upregulated by HNF1A shRNAs. Cells expressed shRNAs constitutively for \>14 days prior to Bru-seq analysis. (**B**) Proportion of HNF1A shRNA-downregulated genes identified in both NY8 and NY15 with HNF1A ChIP-seq peaks. Proximal peaks are ±5 kbp of the transcription start site (TSS) of a given gene and distal peaks are ±100 kbp of a TSS. Peaks are recognized only if they are closer to the TSS of a given gene than to other expressed genes. Peaks overlapping putative enhancer regions (ENCODE) are indicated in dark grey. (**C**) HNF1A ChIP-seq and HNF1A shRNA Bru-seq traces for the genes CDH17 and EPCAM in NY8 and NY15 cells. Traces represent normalized read coverage (in RPKM) across the indicated genomic ranges. MACS-identified ChIP peaks are represented by bars under the corresponding trace. (**D**) Transcription factor (TF) motif over-representation analysis of HNF1A upregulated and downregulated genes (±5 kbp of TSS). The top 10 over-represented TF motifs, ranked by z-score, are listed. (**E**) HNF1A upregulated and bound genes were ranked according to model significance and the direction of survival association using TCGA PDA patient data. Magnitude indicates significance (log~10~-transformed FDR-adjusted Wald p values for Cox PH models) and sign represents survival direction (determined by hazard ratio). Red bars indicate FDR \< 0.1, orange bars indicate FDR \< 0.25, and gray bars are not significant. The FDR thresholds are also indicated by dotted horizontal lines. Insets: each histogram represents the null distribution of a permutation test (N = 10,000) for fraction of genes significantly associated with reduced survival (the tests use FDR thresholds of 0.1 or 0.25, as indicated). Vertical lines represent values for the set of HNF1A target genes; red: FDR \< 0.1 test; orange: FDR \< 0.25 test. \* - indicates significant p value estimates for the permutation tests. Related data found in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.](elife-33947-fig7){#fig7}

To assess genomic binding of HNF1A, we performed ChIP-seq using an HNF1A-specific antibody from NY8 and NY15 (two replicates each). ChIP-seq peaks were called using MACS ([@bib13]) with the *a priori* assumption of narrow, transcription factor-like peaks. Input DNA was used to discern peaks from the background. Peaks were assigned to genes based on proximity and minimum mean expression level (0.25 RPKM) obtained from the Bru-seq data. Common peaks between NY8 and NY15 cells were defined as those peaks with overlap in at least one replicate of both cell lines. Genes were then classified as proximal, distal or neither, given the distance of the closest common peak to the transcription start site (proximal:±5 kb, distal:±100 kb, neither:\>100 kb or no peak). The closest peak to a gene must also identify that gene as its closest gene, to discern among genes with nearby TSSs. 139/239 (57.2%) and 11/46 (23.9%) HNF1A upregulated/downregulated genes had HNF1A binding based on this criteria ([Figure 7B](#fig7){ref-type="fig"}), and supports the role of HNF1A as a transcriptional activator.

To further understand the regulatory role of HNF1A, we asked whether the HNF1A peaks overlapped with enhancer regions. The ENCODE combined segmentation model (a model for regulatory regions based on the ChromHMM and Segway models) was selected for this purpose ([@bib21]; [@bib12]; [@bib20]). Of the six cell lines represented in this data set, it is not clear if any one best represents our PDA cell lines. We therefore extracted regions designated 'strong enhancer' (E) from all the cell lines and merged them into one set of enhancer regions. 72.7% of HNF1A-bound genes had peaks overlapping in at least one of these putative enhancer regions ([@bib10]) ([Figure 7B](#fig7){ref-type="fig"}), suggesting that HNF1A has significant interaction with regulatory regions.

A number of known HNF1A target genes exhibited HNF1A promoter-proximal binding and transcriptional responsiveness via Bru-seq/ChIP-seq, including *CDH17* ([Figure 7C](#fig7){ref-type="fig"}). Additionally, the PCSC marker *EPCAM* also showed HNF1A distal binding and transcriptional responsiveness, implicating HNF1A as a direct regulator of this gene. *CD24*, which showed decreased transcription in response to HNF1A loss, did not show direct binding, indicating an indirect mechanism of regulation (data not shown). *POU5F1/OCT4* transcription was found to decrease in both NY8 (34.3%) and NY15 (41.5%) cells, with weak enrichment of the LTR promoter region (data not shown), further supporting direct regulation of *POU5F1/OCT4* transcription by HNF1A. To determine whether POU5F1/OCT4 contributes to the deregulation of genes by HNF1A knockdown, we tested for overrepresentation of TF-binding motifs in the proximal promoter regions (±5 kbp from TSS) of HNF1A upregulated and downregulated genes using oPOSSUM. The POU5F1/OCT4 motif was the most significantly over-represented transcription factor motif in HNF1A downregulated genes (z-score = 18.381; 13/45 genes). The POU5F1/OCT4 motif was enriched in the HNF1A upregulated genes, though less highly ranked (rank \#60; z-score = 2.104; 47/231 genes; [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Of the predicted POU5F1/OCT4 targets, four have previously been identified (CACNA2D1, GATA2, SNAI1, and ZEB2) (Marsboom et al., [@bib33]; [@bib5]). Additionally, other reported POU5F1/OCT4 targets ([@bib5]) were identified among non-predicted targets, including the HNF1A upregulated genes KLF5 and ZHX2 and the HNF1A downregulated gene GJA1. These data demonstrate an overlap between HNF1A and POU5F1/OCT4 transcriptional networks.

Because CSC and oncogene gene signatures have been linked to prognosis in a variety of cancer types ([@bib4]; [@bib11]; [@bib15]; [@bib40]; [@bib61]), we asked if expression of HNF1-regulated genes was related to survival as a clinical outcome. The TCGA dataset for PDA (PAAD) consists of 178 tumor samples from different patients where both gene expression (RNA-seq) and clinical survival data was collected. Of these, we selected those tumors (n = 169) not identified as histologically neuroendocrine. For each gene, we generated a Cox proportional hazards survival model. We asked what fraction of genes in the HNF1A-responsive genes exhibited significance via Cox regression and whether they were associated with increased or reduced survival (hazard ratio \<1 or\>1, respectively). p Values were FDR-adjusted for multiple testing and two thresholds were explored. 13/237 (5.5%) of HNF1A upregulated genes were associated with reduced survival at FDR \< 0.1 and 57/237 (24.1%) at FDR \< 0.25, with only one gene associated with increased survival passing the FDR \< 0.25 threshold ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). For HNF1A upregulated and bound, we found a similar pattern; 11/137 (8.0%) genes associated with reduced survival and 37/137 (27.0%) genes at FDR \< 0.25 and 0 genes passing the FDR \< 0.25 threshold ([Figure 7E](#fig7){ref-type="fig"}). For HNF1A downregulated genes, 1/45 (2.2%) genes were significant at FDR \< 0.25 only ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). A background set of genes, defined as those genes expressed above a minimal threshold in the Bru-seq data and mappable to gene identifiers in the TCGA data (see Materials and methods, was selected for permutations testing). The permutation tests showed that HNF1A upregulated genes were significantly associated with poorer outcomes versus randomly selected genes (insets, [Figure 7E](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}; see Materials and methods for details). These findings further support the oncogenic role for HNF1A in PDA as a direct regulator of a set of genes associated with poor patient survival.

Discussion {#s3}
==========

In this study, we identified the transcription factor HNF1A as putative regulator of a PCSC gene signature. Functional studies revealed that HNF1A was not only central to the regulation of this gene signature, but also PCSC function. Depletion of HNF1A effectively inhibited PDA cell growth, tumorsphere formation, and tumor growth, with a loss of PCSC marker expression observed both in vitro and in vivo. Mechanistically, HNF1A appears to promote stemness through positive regulation of pluripotency factor POU5F1/OCT4. Finally, we found that expression of HNF1A upregulated genes significantly predicted poor survival outcomes in patients with PDA. These data point to a novel oncogenic role for HNF1A in pancreatic cancer, particularly in promoting PCSC properties.

A clear role for HNF1A in PDA has not previously been established. An early study of the putative oncogene FGFR4, frequently expressed in PDA ([@bib48]), is directly regulated by HNF1A through intronic binding sites ([@bib64]). More recently, 73% of PDA samples were found to stain positive for HNF1A ([@bib24]). A more direct role for HNF1A in PDA has been suggested by multiple GWA studies implicating certain SNPs in HNF1A as risk factors for the development of PDA ([@bib54]; [@bib73]; [@bib32]). Nearly all the identified HNF1A SNPs are non-coding and relatively common (minor allele frequencies between 30 and 40%), suggesting these SNPs may serve as potential contributing rather than driving factors in pancreatic tumorigenesis. Interestingly, PDA-associated HNF1A SNPs rs7310409, rs1169300, and rs2464196 are also associated with both an elevated risk (1.5--2 fold) of developing lung cancer and elevated circulating C-reactive protein (CRP). A well-established direct target of HNF1A ([@bib69]), CRP is downregulated in patients with inactivating mutations in HNF1A ([@bib68]). As several PDA-associated SNPs are associated with elevated CRP, it is therefore possible that these SNPs augment the activity/expression of HNF1A rather than diminish it, as in the case of maturity-onset diabetes of the young 3 (MODY3) variants which reduce or abolish HNF1A expression or function. Still, a tumor suppressive role for HNF1A in PDA has also been proposed ([@bib22]; [@bib35]). In these studies, HNF1A was found to possess pro-apoptotic/anti-proliferative properties contrary to the data in this study. Differences in these results may be technical in nature (control cells in Luo et al. exhibited unusually high baseline apoptosis approaching 50%); however, it is also possible that the role of HNF1A may differ between different molecular subtypes of PDA ([@bib3]) or in a dynamic manner like fellow transcription factor PDX1 ([@bib62]). Supporting the former, HNF1A expression has been proposed as a biomarker to distinguish between the exocrine/ADEX subtype (HNF1A high/KRT81 low) and the quasi-mesenchymal/squamous/basal-like subtype (HNF1A low/KRT81 high) ([@bib44]; [@bib46]), and supports previous observations that the quasi-mesenchymal/squamous/basal-like subtype is associated with poorer prognosis and drug resistance ([@bib3]; [@bib9]; [@bib42]). Although these studies suggest that HNF1A expression may be highest in the exocrine/ADEX subtype of PDA, HNF1A function was not specifically examined. It is possible that like other pancreas-lineage transcription factors, such as PDX1 ([@bib62]) and FOXA1 ([@bib60]), HNF1A is associated with subtypes of PDA that retain elements of pancreatic identity (classical and exocrine/ADEX), but are nonetheless important maintenance of the disease. Interestingly, Noll et al. demonstrated that high expression of CYP3A5 in the exocrine/ADEX subtype mediates resistance to tyrosine kinase inhibitors and paclitaxel. Our work identifies CYP3A5 as a direct target of HNF1A, suggesting that HNF1A may play a direct role in drug resistance in PDA, and future studies should explore this possibility.

While we found an association between HNF1A upregulated genes and poor patient survival, we did not observe a significant association between HNF1A mRNA expression and survival (p=0.7017). As the promoters of HNF1A upregulated genes were enriched for transcription factor known to play roles in PDA including GATA (likely GATA5 or GATA6) ([@bib60]; [@bib39]; [@bib76]), PDX1 ([@bib62]), and SOX9 ([@bib8]; [@bib25]; [@bib70]), it is possible that HNF1A may work in concert with other transcription factors to elicit its full oncogenic function in PDA. A similar interaction between the transcription factors Foxa1 and Gata5 was recently described in driving metastasis in murine models of PDA ([@bib60]).

Our data on HPDE and HPNE cells support a partially transforming capacity for HNF1A, wherein it overcomes contact-inhibition and anchorage-dependent growth. As cooperation with oncogenic KRAS was observed in these cells, it is feasible that HNF1A provides additional oncogenic input, possibly by altering the differentiation state of KRAS-mutant, precancerous pancreatic cells or by expanding the resident stem cell/cancer stem cell population. Indeed, expression of HNF1A alone was sufficient to increase CD24 expression/positivity in both HPDE and HPNE cells.

Typically a marker of endodermal differentiation, HNF1A has not previously been reported as necessary for normal or cancer stem cells. HNF1A plays a critical role in the normal functionality of the endocrine pancreas, with hereditary inactivating mutations in the gene and promoter region resulting in MODY3, an autosomal dominant form of diabetes resulting from β cell insufficiency. Additionally, murine knockout models recapitulate the diabetic phenotype seen in humans ([@bib29]), with elegant transcriptomic work demonstrating a requirement for murine Hnf1a in β cell proliferation ([@bib63]). The role for HNF1A in the exocrine pancreas is less clear, and compared to islet and liver cells in the latter study, we only identified 11 overlapping HNF1A upregulated genes (*ANXA4*, *CEACAM1*, *CHKA*, *DPP4*, *HNF4A*, *HSD17B2*, *LGALS3*, *MTMR11*, *NR0B2*, *SLC16A5*, *TM4SF4*), suggesting distinct activity for HNF1A in PDA compared to either β cells or the liver. Regulation of *POU5F1/OCT4* transcription by HNF1A is an especially exciting finding, connecting HNF1A with a previously unidentified role in regulating stemness. Our study identifies a recently described LTR promoter region ([@bib37]), upstream from the canonical POU5F1/OCT4 promoter, as a likely region of direct transcriptional regulation of POU5F1/OCT4 by HNF1A, supported by both ChIP and reporter assays ([Figure 6---figure supplement 1B,D](#fig6s1){ref-type="fig"}). As this promoter region, is not conserved between humans and rodents, it is possible the interaction between HNF1A and POU5F1/OCT4 is an acquisition of human evolution and may explain why POU5F1/OCT4 has not previously been identified as an HNF1A target. Interestingly, a recent study SPINK1-positive castrate resistant prostate cancer identified *POU5F1/OCT4* as part of a gastrointestinal gene signature present in SPINK1-positive prostate cancer and regulated by HNF1A and its target gene HNF4G ([@bib65]). Consistent with our findings, this study showed downregulation/upregulation of *POU5F1/OCT4* mRNA in response to HNF1A knockdown/overexpression, respectively. While direct regulation of POU5F1/OCT4 and HNF1A was not explored in this study, it does support an association between these two transcription factors, not only in gastrointestinal cells, but other cancers as well. This could indicate a more general role for HNF1A in regulating stem cell properties in human cells in which it is normally expressed.

Given that HNF1A upregulated genes were found to be significantly associated with poor survival in patients with PDA, it is likely that multiple target genes contribute to HNF1A's oncogenic influence, and future studies should be done to assess the functions of these genes in PDA to ascertain their value as either potential biomarkers or therapeutic targets. Further studies are also needed in regards to HNF1A's role in the exocrine pancreas and whether its function is redirected during the development of PDA, particularly under the influence of oncogenic KRAS. Overall, this study further validates the importance of HNF1A to PDA while providing a novel and critical role for HNF1A in driving pancreatic cancer stem cell properties.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation                         Source or reference                      Identifiers                                                         Additional information
  (species) or resource                                                                                                                                                    
  ----------------------- ----------------------------------- ---------------------------------------- ------------------------------------------------------------------- --------------------------------
  Gene (Human)            HNF1A                               This paper                                                                                                   Cloned from NY5 cDNA

  Gene\                   LacZ                                Invitrogen                               Originally from Catalog\                                            Subcloned into\
  (*Escherichia coli*)                                                                                 number: K499000                                                     pLentipuro3/TO/V5-DEST

  Gene\                   PatGFP                              This paper                                                                                                   Variant of EGFP containing\
  (Aequorea victoria)                                                                                                                                                      the following mutations:\
                                                                                                                                                                           S31R, Y40N, S73A, F100S,\
                                                                                                                                                                           N106T, Y146F, N150K, M154T,\
                                                                                                                                                                           V164A, I168T, I172V, A207V

  Gene (Human)            KRAS G12D                           This paper                                                                                                   Cloned from NY5 cDNA

  Gene (Human)            POU5F1 (OCT4A)                      Transomic\                               Catalog number:\                                                    Subcloned into pLenti6.3\
                                                              Technologies                             BC117435                                                            /UbC/V5-DEST

  Gene\                   LacZ2.1 shRNA                       This paper                                                                                                   Sequence: CACCAAATCGCTGATTT\
  (*Escherichia coli*)                                                                                                                                                     GTGTAGTCGTTCAAGAGACGACT\
                                                                                                                                                                           ACACAAATCAGCGA

  Gene (Human)            HNF1A shRNA\#1                      This paper                                                                                                   Sequence: CACCGCTAGTGGAGGA\
                                                                                                                                                                           GTGCAATTTCAAGAGAATTGCACTC\
                                                                                                                                                                           CTCCACTAGC

  Gene (Human)            HNF1A shRNA\#2                      This paper                                                                                                   Sequence: CACCGTCCCTTAGTGA\
                                                                                                                                                                           CAGTGTCTATTCAAGAGATAGA\
                                                                                                                                                                           CACTGTCACTAAGGGAC

  Gene\                   IVS-TetR-P2A-Bsd                    This paper                                                                                                   IVS-TetR and Bsd were\
  (*Escherichia coli*)                                                                                                                                                     subcloned from pLenti6/TR\
                                                                                                                                                                           (Invitrogen) with a P2A\
                                                                                                                                                                           peptide linker added by PCR\
                                                                                                                                                                           and Gibson Assembly

  Gene\                   PatGFP-Luc2                         This paper                                                                                                   PatGFP and Luc2 (Promega)\
  (Aequorea victoria)                                                                                                                                                      were amplified by PCR and\
                                                                                                                                                                           fused by Gibson Assembly

  Strain, strain\         NOD.CB17-*Prkdc^scid^*/J            The Jackson\                             Catalog number:\                                                    
  background\                                                 Laboratory                               001303; RRID:\                                                      
  (Mouse)                                                                                              [IMSR_JAX:001303](https://scicrunch.org/resolver/IMSR_JAX:001303)   

  Cell line (Human)       HPDE                                Craig Logsdon,\                                                                                              
                                                              MD Anderson                                                                                                  

  Cell line (Human)       HPNE                                ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC CRL-4023;\                                                     
                                                                                                       RRID:[CVCL_C466](https://scicrunch.org/resolver/CVCL_C466)          

  Cell line (Human)       Capan-2                             ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC HTB-80;\                                                       
                                                                                                       RRID:[CVCL_0026](https://scicrunch.org/resolver/CVCL_0026)          

  Cell line (Human)       HPAF-II                             ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC CRL-1997;\                                                     
                                                                                                       RRID:[CVCL_0313](https://scicrunch.org/resolver/CVCL_0313)          

  Cell line (Human)       BxPC-3                              ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC CRL-1687;\                                                     
                                                                                                       RRID:[CVCL_0186](https://scicrunch.org/resolver/CVCL_0186)          

  Cell line (Human)       AsPC-1                              ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC CRL-1682;\                                                     
                                                                                                       RRID:[CVCL_0152](https://scicrunch.org/resolver/CVCL_0152)          

  Cell line (Human)       MiaPaCa-2                           ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC CRL-1420;\                                                     
                                                                                                       RRID:[CVCL_0428](https://scicrunch.org/resolver/CVCL_0428)          

  Cell line (Human)       Panc-1                              ATCC                                     Catalog number:\                                                    
                                                                                                       ATCC CRL-1469;\                                                     
                                                                                                       RRID:[CVCL_0480](https://scicrunch.org/resolver/CVCL_0480)          

  Cell line (Human)       NY1                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line\
                                                                                                                                                                           established from xenograft

  Cell line (Human)       NY2                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY3                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY5                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY6                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY8                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY9                                 This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY12                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY15                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY16                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY17                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY19                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY28                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY32                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       NY53                                This paper                                                                                                   Low passage pancreatic\
                                                                                                                                                                           adenocarcinoma patient\
                                                                                                                                                                           primary cell line established\
                                                                                                                                                                           from xenograft

  Cell line (Human)       293FT                               Invitrogen                               Catalog number:\                                                    
                                                                                                       R70007                                                              

  Transfected\            pTK-GDLuc                           This paper                                                                                                   The Gaussia coding region\
  construct (Gaussia)                                                                                                                                                      of pTK-Gluc (New England\
                                                                                                                                                                           Biolabs) was replaced with\
                                                                                                                                                                           the Gaussia Dura coding\
                                                                                                                                                                           region (Millipore)

  Transfected\            pCLuc-Basic2                        New England\                             Catalog number:\                                                    
  construct (Cypridina)                                       Biolabs                                  N0317S                                                              

  Transfected\            pCLuc-Basic2/OCT4\                  This paper                                                                                                   1.7 kbp OCT4 LTR\
  construct (Cypridina)   LTR promoter                                                                                                                                     promoter region from NY5\
                                                                                                                                                                           was subcloned into\
                                                                                                                                                                           pCLuc-Basic2

  Transfected\            pCLuc-Basic2/OCT4\                  This paper/Addgene                       Originally from\                                                    OCT4 promoter from\
  construct (Cypridina)   canonical promoter                                                           Catalog number:\                                                    phOct4-EGFP (Addgene)\
                                                                                                       38776                                                               was subcloned into\
                                                                                                                                                                           pCLuc-Basic2

  Antibody                CD326 (EpCAM)-FITC                  Miltenyi Biotec                          Catalog number:\                                                    Application:\
                                                                                                       130-113-263;\                                                       flow cytometry
                                                                                                       RRID:[AB_2726064](https://scicrunch.org/resolver/AB_2726064)        

  Antibody                BD Pharmingen APC\                  BD Biosciences                           Catalog number:\                                                    Application:\
                          Mouse Anti-Human\                                                            559942;\                                                            flow cytometry
                          CD44                                                                         RRID:[AB_398683](https://scicrunch.org/resolver/AB_398683)          

  Antibody                BD Pharmingen\                      BD Biosciences                           Catalog number:\                                                    Application:\
                          PE Mouse Anti-Human\                                                         555428;\                                                            flow cytometry
                          CD24                                                                         RRID:[AB_395822](https://scicrunch.org/resolver/AB_395822)          

  Antibody                H-2Kd/H-2Dd\                        SouthernBiotech                          Catalog number:\                                                    Application:\
                          clone 34-1-2S                                                                1911--08;\                                                          flow cytometry
                                                                                                       RRID:[AB_1085008](https://scicrunch.org/resolver/AB_1085008)        

  Antibody                Anti-HNF1 antibody\                 Abcam                                    Catalog number:\                                                    Application:\
                          \[GT4110\]                                                                   ab184194;\                                                          IHC, Western blot
                                                                                                       RRID:[AB_2538735](https://scicrunch.org/resolver/AB_2538735)        

  Antibody                HNF-1 alpha Antibody\               Santa Cruz\                              Catalog number:\                                                    ChIP
                          (C-19)                              Biotechnology                            sc-6547;\                                                           
                                                                                                       RRID:[AB_648295](https://scicrunch.org/resolver/AB_648295)          

  Antibody                Normal Rabbit IgG                   Cell Signaling\                          Catalog number:\                                                    ChIP
                                                              Technology                               2729S;\                                                             
                                                                                                       RRID:[AB_1031062](https://scicrunch.org/resolver/AB_1031062)        

  Antibody                HNF1α (D7Z2Q)                       Cell Signaling\                          Catalog number:\                                                    Application:\
                                                              Technology                               89670S;\                                                            Western blot
                                                                                                       RRID:[AB_2728751](https://scicrunch.org/resolver/AB_2728751)        

  Antibody                β-Actin (clone AC-74)               Sigma Aldrich                            Catalog number:\                                                    Application:\
                                                                                                       A2228-200UL;\                                                       Western blot
                                                                                                       RRID:[AB_476697](https://scicrunch.org/resolver/AB_476697)          

  Antibody                CDH17 antibody                      Proteintech                              Catalog number:\                                                    Application:\
                                                                                                       50-608-369;\                                                        Western blot
                                                                                                       RRID:[AB_2728752](https://scicrunch.org/resolver/AB_2728752)        

  Antibody                DPP4/CD26 (D6D8K)                   Cell Signaling\                          Catalog number:\                                                    Application:\
                                                              Technology                               67138S;\                                                            Western blot
                                                                                                       RRID:[AB_2728750](https://scicrunch.org/resolver/AB_2728750)        

  Antibody                CD44 (156--3 C11)                   Cell Signaling\                          Catalog number:\                                                    Application:\
                                                              Technology                               3570S;\                                                             Western blot
                                                                                                       RRID:[AB_10693293](https://scicrunch.org/resolver/AB_10693293)      

  Antibody                EpCAM (D1B3)                        Cell Signaling\                          Catalog number:\                                                    Application:\
                                                              Technology                               2626S;\                                                             Western blot
                                                                                                       RRID:[AB_2728749](https://scicrunch.org/resolver/AB_2728749)        

  Antibody                Cleaved Caspase-3\                  Cell Signaling\                          Catalog number:\                                                    Application:\
                          (Asp175) (5A1E)                     Technology                               9664S;\                                                             Western blot
                                                                                                       RRID:[AB_2070042](https://scicrunch.org/resolver/AB_2070042)        

  Antibody                Cleaved Caspase-6\                  Cell Signaling\                          Catalog number:\                                                    Application:\
                          (Asp162)                            Technology                               9761S;\                                                             Western blot
                                                                                                       RRID:[AB_2290879](https://scicrunch.org/resolver/AB_2290879)        

  Antibody                Cleaved Caspase-7\                  Cell Signaling\                          Catalog number:\                                                    Application:\
                          (Asp198) (D6H1)                     Technology                               8438S; R\                                                           Western blot
                                                                                                       RID:[AB_11178377](https://scicrunch.org/resolver/AB_11178377)       

  Antibody                Cleaved Caspase-9\                  Cell Signaling\                          Catalog number:\                                                    Application:\
                          (Asp330) (D2D4)                     Technology                               7237S;\                                                             Western blot
                                                                                                       RRID:[AB_10895832](https://scicrunch.org/resolver/AB_10895832)      

  Antibody                Cleaved Caspase-9\                  Cell Signaling\                          Catalog number:\                                                    Application:\
                          (Asp315) Antibody                   Technology                               9505S;\                                                             Western blot
                                                                                                       RRID:[AB_2290727](https://scicrunch.org/resolver/AB_2290727)        

  Antibody                GFP (D5.1) XP                       Cell Signaling\                          Catalog number:\                                                    Application:\
                                                              Technology                               2956S;\                                                             Western blot
                                                                                                       RRID:[AB_1196615](https://scicrunch.org/resolver/AB_1196615)        

  Antibody                Ras (G12D Mutant\                   Cell Signaling\                          Catalog number:\                                                    Application:\
                          Specific) (D8H7)                    Technology                               14429S;\                                                            Western blot
                                                                                                       RRID:[AB_2728748](https://scicrunch.org/resolver/AB_2728748)        

  Antibody                Phospho-p44/42 MAPK\                Cell Signaling\                          Catalog number:\                                                    Application:\
                          (Erk1/2)\                           Technology                               4370S;\                                                             Western blot
                          (Thr202/Tyr204)\                                                             RRID:[AB_2315112](https://scicrunch.org/resolver/AB_2315112)        
                          (D13.14.4E) XP                                                                                                                                   

  Antibody                Phospho-Akt (Ser473)\               Cell Signaling\                          Catalog number:\                                                    Application:\
                          (D9E) XP                            Technology                               4060S;\                                                             Western blot
                                                                                                       RRID:[AB_2315049](https://scicrunch.org/resolver/AB_2315049)        

  Antibody                Oct-4A (C52G3)                      Cell Signaling\                          Catalog number:\                                                    Application:\
                                                              Technology                               2890S;\                                                             Western blot
                                                                                                       RRID:[AB_2167725](https://scicrunch.org/resolver/AB_2167725)        

  Antibody                Anti-KRAS + HRAS +\                 Abcam                                    Catalog number:\                                                    Application:\
                          NRAS antibody                                                                ab55391;\                                                           Western blot
                                                                                                       RRID:[AB_941040](https://scicrunch.org/resolver/AB_941040)          

  Antibody                Anti-β-Galactosidase                Promega                                  Catalog number:\                                                    Application:\
                                                                                                       Z3781;\                                                             Western blot
                                                                                                       RRID:[AB_430877](https://scicrunch.org/resolver/AB_430877)          

  Antibody                IRDye 800CW Goat\                   Licor                                    Catalog number:\                                                    Application:\
                          anti-Mouse IgG                                                               926--32210;\                                                        Western blot
                                                                                                       RRID:[AB_621842](https://scicrunch.org/resolver/AB_621842)          

  Antibody                IRDye 800CW Goat\                   Licor                                    Catalog number:\                                                    Application:\
                          anti-Rabbit                                                                  926--32211;\                                                        Western blot
                                                                                                       RRID:[AB_621843](https://scicrunch.org/resolver/AB_621843)          

  Antibody                IRDye 680LT goat\                   Licor                                    Catalog number:\                                                    Application:\
                          anti-mouse                                                                   926--68020;\                                                        Western blot
                                                                                                       RRID:[AB_10706161](https://scicrunch.org/resolver/AB_10706161)      

  Antibody                IRDye 680LT Goat\                   Licor                                    Catalog number:\                                                    Application:\
                          anti-Rabbit IgG                                                              926--68021;\                                                        Western blot
                                                                                                       RRID:[AB_10706309](https://scicrunch.org/resolver/AB_10706309)      

  Recombinant\            pLentipuro3/TO/\                    Andrew E. Aplin,\                                                                                            
  DNA reagent             V5-DEST                             Thomas Jefferson\                                                                                            
                                                              University                                                                                                   

  Recombinant\            pLentineo3/TO/\                     Andrew E. Aplin,\                                                                                            
  DNA reagent             V5-DEST                             Thomas Jefferson\                                                                                            
                                                              University                                                                                                   

  Recombinant\            pLentihygro3/TO/\                   Andrew E. Aplin,\                                                                                            
  DNA reagent             V5-DEST                             Thomas Jefferson\                                                                                            
                                                              University                                                                                                   

  Recombinant\            pLenti0.3/EF/\                      This paper                                                                                                   Human EF1-alpha\
  DNA reagent             V5-DEST                                                                                                                                          promoter was substituted\
                                                                                                                                                                           for the CMV promoter of\
                                                                                                                                                                           pLenti6.3/UbC/V5-DEST\
                                                                                                                                                                           and the SV40 promoter/Bsd\
                                                                                                                                                                           cassette was removed

  Recombinant\            pLenti6.3/UbC/\                     Andrew E. Aplin,\                                                                                            
  DNA reagent             V5-DEST                             Thomas Jefferson\                                                                                            
                                                              University                                                                                                   

  Recombinant\            pLenti6.3/UbC\                      This paper                                                                                                   EcoRV digest/re-ligation\
  DNA reagent             empty vector                                                                                                                                     to remove Gateway element

  Recombinant\            pLentipuro3/\                       Andrew E. Aplin,\                                                                                            
  DNA reagent             Block-iT-DEST                       Thomas Jefferson\                                                                                            
                                                              University                                                                                                   

  Recombinant\            pLenti0.3/EF/GW/IVS\                This paper                                                                                                   LR recombination of\
  DNA reagent             -Kozak-TetR-P2A-Bsd                                                                                                                              IVS-TetR-P2A-Bsd cassette\
                                                                                                                                                                           into pLenti0.3/EF/V5-DEST

  Recombinant\            pLenti0.3/EF/GW/\                   This paper                                                                                                   LR recombination of\
  DNA reagent             PatGFP-Luc2                                                                                                                                      PatGFP-Luc2 cassette\
                                                                                                                                                                           into pLenti0.3/EF/V5-DEST

  Recombinant\            pLP1                                Andrew E. Aplin,\                                                                                            Lentivirus packaging\
  DNA reagent                                                 Thomas Jefferson\                                                                                            plasmid originally from\
                                                              University                                                                                                   Invitrogen

  Recombinant\            pLP2                                Andrew E. Aplin,\                                                                                            Lentivirus packaging\
  DNA reagent                                                 Thomas Jefferson\                                                                                            plasmid originally from\
                                                              University                                                                                                   Invitrogen

  Recombinant\            pLP/VSVG                            Andrew E. Aplin,\                                                                                            Lentivirus packaging\
  DNA reagent                                                 Thomas Jefferson\                                                                                            plasmid originally from\
                                                              University                                                                                                   Invitrogen

  Sequence-based\         Non-targeting\                      Dharmacon                                Catalog number:\                                                    
  reagent                 control siRNA                                                                D-001810-01-20                                                      

  Sequence-based\         HNF1A siRNA \#1                     Dharmacon                                Catalog number:\                                                    Sequence:\
  reagent                                                                                              D-008215-01-0002                                                    GGAGGAACCGTTTCAAGTG

  Sequence-based\         HNF1A siRNA \#2                     Dharmacon                                Catalog number:\                                                    Sequence:\
  reagent                                                                                              D-008215-02-0002                                                    GCAAAGAGGCACTGATCCA

  Sequence-based\         POU5F1/OCT4\                        Dharmacon                                Catalog number:\                                                    Sequence:\
  reagent                 siRNA \#5                                                                    D-019591-05-0002                                                    CATCAAAGCTCTGCAGAAA

  Sequence-based\         POU5F1/OCT4\                        Dharmacon                                Catalog number:\                                                    Sequence:\
  reagent                 siRNA \#6                                                                    D-019591-06-0002                                                    GATATACACAGGCCGATGT

  Sequence-based\         POU5F1/OCT4\                        Dharmacon                                Catalog number:\                                                    Sequence:\
  reagent                 siRNA \#9                                                                    D-019591-09-0002                                                    GCGATCAAGCAGCGACTAT

  Sequence-based\         POU5F1/OCT4\                        Dharmacon                                Catalog number:\                                                    Sequence:\
  reagent                 siRNA \#10                                                                   D-019591-10-0002                                                    TCCCATGCATTCAAACTGA

  Peptide,\               Recombinant\                        Invitrogen                               Catalog number:\                                                    
  recombinant protein     human EGF                                                                    PHG0311L                                                            

  Peptide,\               FGF-basic\                          Invitrogen                               Catalog number:\                                                    
  recombinant protein     Recombinant\                                                                 PHG0264                                                             
                          Human                                                                                                                                            

  Peptide,\               Leukemia\                           Sigma Aldrich                            Catalog number:\                                                    
  recombinant protein     Inhibitory Factor\                                                           L5283                                                               
                          human                                                                                                                                            

  Peptide,\               Bone Morphogenetic\                 Peprotech                                Catalog number:\                                                    
  recombinant protein     Protein four human                                                           120--05                                                             

  Commercial\             SimpleChIP Enzymatic\               Cell Signaling\                          Catalog number:\                                                    
  assay or kit            Chromatin IP Kit\                   Technology                               9003                                                                
                          (Magnetic Beads)                                                                                                                                 

  Commercial\             BioLux *Gaussia*\                   New England\                             Catalog number:\                                                    
  assay or kit            Luciferase Assay Kit                Biolabs                                  E3300S                                                              

  Commercial\             BioLux\                             New England\                             Catalog number:\                                                    
  assay or kit            *Cypridina* Luciferase\             Biolabs                                  E3309S                                                              
                          Assay Kit                                                                                                                                        

  Commercial\             RNeasy Plus Mini\                   Qiagen                                   Catalog number:\                                                    
  assay or kit            Kit coupled with\                                                            74136 and 79254                                                     
                          RNase-free DNase set                                                                                                                             

  Commercial\             High Capacity\                      Applied\                                 Catalog number:\                                                    
  assay or kit            RNA-to-cDNA Master\                 Biosystem                                4387406                                                             
                          Mix                                                                                                                                              

  Commercial\             Power SYBR Green\                   Applied\                                 Catalog number:\                                                    
  assay or kit            PCR Master Mix                      Biosystem                                4367659                                                             

  Chemical\               APC-Cy7 Streptavidin                BD Biosciences                           Catalog number:\                                                    
  compound, drug                                                                                       554063                                                              

  Chemical\               DAPI\                               Invitrogen                               Catalog number:\                                                    
  compound, drug          (4\',6-Diamidino-2-Phenylindole,\                                            3571                                                                
                          Dilactate)                                                                                                                                       

  Chemical\               APC Annexin V                       BD Biosciences                           Catalog number:\                                                    
  compound, drug                                                                                       550474                                                              

  Chemical\               Annexin V Binding\                  BD Biosciences                           Catalog number:\                                                    
  compound, drug          Buffer, 10x concentrate                                                      556454                                                              

  Chemical\               RNase A                             Invitrogen                               Catalog number:\                                                    
  compound, drug                                                                                       12091021                                                            

  Chemical\               Lipofectamine 2000\                 Invitrogen                               Catalog number:\                                                    
  compound, drug          Reagent                                                                      11668019                                                            

  Chemical\               Lipofectamine RNAiMAX\              Invitrogen                               Catalog number:\                                                    
  compound, drug          Reagent                                                                      13778150                                                            

  Chemical\               Propidium iodide                    Invitrogen                               Catalog number:\                                                    
  compound, drug                                                                                       P1304MP                                                             

  Chemical\               Gentamicin                          Invitrogen                               Catalog number:\                                                    
  compound, drug                                                                                       15710072                                                            

  Chemical\               Antibiotic-Antimycotic (100X)       Invitrogen                               Catalog number:\                                                    
  compound, drug                                                                                       15240062                                                            

  Chemical\               N-2 Supplement (100X)               Invitrogen                               Catalog number:\                                                    
  compound, drug                                                                                       17502--048                                                          

  Chemical\               B-27 Serum-Free\                    Invitrogen                               Catalog number:\                                                    
  compound, drug          Supplement (50X)                                                             17504--044                                                          

  Chemical\               Doxycycline                         Sigma Aldrich                            D9891-100G                                                          
  compound, drug                                                                                                                                                           

  Software,\              GraphPad Prism 6                    GraphPad Software;\                      RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)        
  algorithm                                                   <http://www.graphpad.com>                                                                                    

  Software,\              oPOSSUM 3.0                         <http://opossum.cisreg.ca/oPOSSUM3/>;\   RRID:[SCR_010884](https://scicrunch.org/resolver/SCR_010884)        
  algorithm                                                   PMID: 22973536                                                                                               

  Software,\              Bowtie v1.1.1                       PMID: 19261174                           RRID:[SCR_005476](https://scicrunch.org/resolver/SCR_005476)        
  algorithm                                                                                                                                                                

  Software,\              Bowtie v0.12.8                      PMID: 19261174                           RRID:[SCR_005476](https://scicrunch.org/resolver/SCR_005476)        
  algorithm                                                                                                                                                                

  Software,\              MACS v1.4.2                         PMID: 18798982                           RRID:[SCR_013291](https://scicrunch.org/resolver/SCR_013291)        
  algorithm                                                                                                                                                                

  Software,\              TopHat v1.4.1                       PMID: 19289445                           RRID:[SCR_013035](https://scicrunch.org/resolver/SCR_013035)        
  algorithm                                                                                                                                                                

  Software,\              DESeq v1.24.0                       PMID: 20979621                           RRID:[SCR_000154](https://scicrunch.org/resolver/SCR_000154)        
  algorithm                                                                                                                                                                

  Software,\              bedtools v.2.26.0                   PMID: 20110278                           RRID:[SCR_006646](https://scicrunch.org/resolver/SCR_006646)        
  algorithm                                                                                                                                                                

  Software,\              survival v2.40--1                   DOI: 10.1007/978-1-4757-3294-8                                                                               
  algorithm                                                                                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Tumor growth assays {#s4-1}
-------------------

Eight- to 10-week-old, evenly sex-mixed NOD/SCID mice were used for all experiments. Orthotopic implantation of PDA cells to the pancreas has previously been described ([@bib1]). Briefly, mice were anesthetized with an intraperitoneal injection of 100 mg/kg ketamine/5 mg/kg xylazine, and a small left subcostal incision was performed. 10,000 PatGFP-Luc2-labeled tumor cells in a volume of 50 µl (1:1 vol of cell suspension in growth media and Matrigel) were injected into the tail of the pancreas using a 30-gauge needle. Weekly bioluminescent imaging of implanted orthotopic tumors in mice was performed using a Xenogen IVIS 200 Imaging System (Xenogen Biosciences, Cranbury, NJ). For subcutaneous implantation of tumor cells, 10,000 tumor cells in a volume of 50 µl (1:1 vol of cell suspension in growth media and Matrigel) was injected subcutaneously into both the left and right midflank regions of mice. Tumor growth was monitored weekly by digital caliper and tumor volumes calculated by the (length x width^2^)/2 method. All mice were sacrificed once any tumors reached 20 mm^3^ in volume.

Immunofluorescence and immunohistochemistry {#s4-2}
-------------------------------------------

Formalin-fixed, paraffin-embedded tumor samples were sectioned and processed for immunofluorescent staining by the University of Michigan ULAM Pathology Cores for Animal Research. Immunohistochemistry was performed using a Ventana BenchMark Ultra autostainer. HNF1A antibody (GT4110) was used for immunohistochemistry at a 1:100 dilution. A PDA/normal pancreas tissue microarray was generated by the University of Michigan Department of Pathology.

Microscopy {#s4-3}
----------

All microscopies were performed on an Olympus IX83 motorized inverted microscope with cellSens Dimension software (Olympus Corporation, Waltham, MA).

Lentiviral constructs {#s4-4}
---------------------

Lentiviral destination vectors were generously provided by Dr. Andrew Aplin (Thomas Jefferson University). For construction of HNF1A, KRAS^G12D^, GFP and LacZ cDNA lentiviruses, pLentipuro3/TO/V5-DEST, pLentineo3/TO/V5-DEST, pLentihygro3/TO/V5-DEST were used. For OCT4A, pLenti6.3/UbC/V5-DEST was used. An EcoRV digested/re-ligated pLenti6.3/UbC/V5-DEST (removing the Gateway cloning element) was used as an empty vector control. For construction of shRNA lentiviruses, pLentipuro3/BLOCK-iT-DEST was used. Human HNF1A and KRAS^G12D^ were cloned from primary PDA cDNA into pENTR/D-TOPO (Invitrogen). Human OCT4A was cloned from pCR4-TOPO clone BC117435 (Transomic Technologies) into pENTR/D-TOPO. LacZ and PatGFP (a variant of EGFP containing the following mutations: S31R, Y40N, S73A, F100S, N106T, Y146F, N150K, M154T, V164A, I168T, I172V, A207V) were also cloned into pENTR/D-TOPO as control proteins. For labeling cells with firefly luciferase, PatGFP was fused to the N-terminus of firefly luciferase Luc2 (subcloned from pGL4.10) and cloned into pENTR/D-TOPO using Gibson Assembly (New England Biolabs). PatGFP-Luc2 was recombined into pLenti0.3/EF/V5-DEST, a modified version of pLenti6.3/UbC/V5-DEST with the human EF-1α promoter instead of the human UbC promoter and no downstream promoter/selective marker cassette, to generate pLenti0.3/EF/GW/PatGFP-Luc2. To generate doxycycline-inducible cell lines, a cassette containing the IVS-TetR region from pLenti6/TR (Invitrogen) was subcloned into pLenti0.3/EF/V5-DEST, along with a C-terminal P2A peptide-blasticidin resistance gene (Bsd) reading frame to generate pLenti0.3/EF/GW/IVS-Kozak-TetR-P2A-Bsd. The resultant lentiviruses were used to transduce NY8, NY15, NY53, and HPDE to generate doxycycline-inducible 'TR' lines. To generate the HNF1A-responsive reporter, the multiple cloning site and minimal promoter from pTA-Luc (Takara, Mountain View, CA) was subcloned upstream of PatGFP. Eight tandem repeats of the HNF1A-binding site with spacer nucleotides (CTTGGTTAATGATTAACCAGA) was cloned between the MluI and BglII sites of the multiple cloning site. LacZ2.1 (CACCAAATCGCTGATTTGTGTAGTCGTTCAAGAGACGACTACACAAATCAGCGA), HNF1A shRNA\#1 (CACCGCTAGTGGAGGAGTGCAATTTCAAGAGAATTGCACTCCTCCACTAGC), and HNF1A shRNA\#2 (CACCGTCCCTTAGTGACAGTGTCTATTCAAGAGATAGACACTGTCACTAAGGGAC) were cloned into pENTR/H1/TO (Invitrogen). cDNA and shRNA constructs were recombined into their respective lentiviral plasmids using LR Clonase II (Invitrogen). The resulting constructs were packaged in 293FT cells as previously described.

siRNA sequences {#s4-5}
---------------

Non-targeting control (Cat\#D-001810--01)

HNF1A-targeting siRNA\#1 (GGAGGAACCGTTTCAAGTG)

HNF1A-targeting siRNA\#2 (GCAAAGAGGCACTGATCCA)

POU5F1/OCT4-targeting siRNA\#5 (CATCAAAGCTCTGCAGAAA)

POU5F1/OCT4-targeting siRNA\#6 (GATATACACAGGCCGATGT)

POU5F1/OCT4-targeting siRNA\#9 (GCGATCAAGCAGCGACTAT)

POU5F1/OCT4-targeting siRNA\#10 (TCCCATGCATTCAAACTGA)

Cell lines {#s4-6}
----------

HPDE cells were a generous gift from Dr. Craig Logsdon (MD Anderson). HPNE, Capan-2, HPAF-II, BxPC-3, AsPC-1, Panc-1, and MiaPaCa-2 cells were purchased from ATCC (Manassas, VA). For all low-passage human primary PDA cells, primary PDA xenograft tumors were cut into small pieces with scissors and then minced completely using sterile scalpel blades. Single cells were obtained described previously ([@bib30]). The cells used in this article are passaged less than 10 times in vitro. All cells were authenticated by STR profiling (University of Michigan DNA Sequencing Core). Cells were routinely tested for mycoplasma contamination using the MycoScope PCR Detection kit (Genlantis, San Diego, CA) and only mycoplasma-free cells were used for experimentation. ATCC and primary PDA cells were cultured in RPMI-1640 with GlutaMAX-I supplemented with 10% FBS (Gibco), 1% antibiotic-antimycotic (Gibco), and 100 µg/ml gentamicin (Gibco). HPDE cells were maintained in keratinocyte SFM supplemented (Invitrogen) with included EGF and bovine pituitary extract as well as 1% antibiotic-antimycotic and 100 µg/ml gentamicin.

Soft agar assays {#s4-7}
----------------

Low-melting agarose (Invitrogen) was dissolved in serum-free RPMI-1640 with GlutaMAX-I to a final concentration of 2% at 60°C and cooled to 42°C. 200 µL per well 2% agarose was evenly spread at the bottom of a 24-well dish, followed by 250 µL of 0.6% agarose (diluted with complete keratinocyte SFM and supplemented with FBS to 2.5%), a 250 µL of 0.4% agarose/cell suspension, and a 250 µL of acellular 0.4% agarose. Each layer was allowed to solidify a 4°C for 10 min and then heated to 37°C prior to adding the next layer. 500 µl of complete keratinocyte SFM and supplemented with 2.5% FBS was added atop each gel and replenished every 3 days.

Flow cytometry {#s4-8}
--------------

Flow cytometry was performed as described previously ([@bib30]). Cells were dissociated with 2.5% trypsin/EDTA solution, counted and transferred to 5 mL tubes, washed with HBSS supplemented with FBS twice and resuspended in HBSS/2% FBS at a concentration of 1 million cells/100 µL. Primary antibodies were diluted 1:40 in cell suspensions and incubated for 30 min on ice with occasional vortexing. Cells were washed twice with HBSS/2% FBS and incubated for 20 min on ice with APC-Cy7 Streptavidin diluted 1:200. Cells were washed twice with HBSS/2% FBS and resuspended in HBSS/2%FBS containing 3 µM 4\',6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA). Flow cytometry and sorting was done using a FACSAria (BD Biosciences, Franklin Lakes, NJ). Side scatter and forward scatter profiles were used to eliminate cell doublets, APC-Cy7 was used to exclude mouse cells. For PatGFP-Luc2 labeling, GFP+/DAPI- cells were isolated by sorting and expanded for one passage prior to implantation. For analysis of apoptosis, APC-conjugated Annexin V and Annexin V binding buffer (BD Biosciences) was used following manufacturer's recommendations with 3 µM DAPI added immediately before analysis to stain permeable cells/necrotic debris.

Propidium iodide staining {#s4-9}
-------------------------

Cells were trypsinized, washed in PBS and fixed in 70% ethanol for 4 hr. Cells were then permeabilized with PBS containing 0.1% Triton X100 and 200 µg/ml RNase A for 2 hr at 37°C and stained with 167 µg/ml propidium iodide for 30 min. DNA content was measured by flow cytometry on a CytoFLEX flow cytometer (Beckman Coulter) and analyzed Summit v6.2 software (Beckman Coulter).

Microarray analysis {#s4-10}
-------------------

Flow sorted NY8 and NY15 P1, P2, and P3 cells were immediately used for RNA isolation using the RNeasy Plus Mini Kit coupled with RNase-free DNase set (Qiagen). Microarrays and analyses were performed by the University of Michigan DNA Sequencing Core. RNA labeling and hybridization was conducted using the Human Genome U133 Plus 2.0 microarray (Affymetrix, Santa Clara, CA). Probe signals were normalized and corrected according to background signal. Adjusted signal strength was used to generate quantitative raw values, which were log-transformed for all subsequent analyses.

Transcription-factor-binding site analysis {#s4-11}
------------------------------------------

For both the PCSC-enriched genes (related to [Figure 1](#fig1){ref-type="fig"}) and the HNF1A target genes (related to [Figure 7](#fig7){ref-type="fig"}), oPOSSUM 3.0 (<http://opossum.cisreg.ca/oPOSSUM3/>) ([@bib27]) was used to detect over-represented conserved transcription factor binding sites. The program was run using the following options: conservation cutoff of 0.4, matrix score threshold of 85%, and search region of 5 kbp, upstream and downstream of the transcription start site. The query was entered against a background of 24,752 genes in the oPOSSUM database.

Quantitative reverse transcription-PCR (qRT-PCR) {#s4-12}
------------------------------------------------

Total RNA was extracted using RNeasy Plus Mini Kit coupled with RNase-free DNase set (Qiagen) and reverse transcribed with High Capacity RNA-to-cDNA Master Mix

(Applied Biosystem). The resulting cDNAs were used for PCR using Power SYBR Green PCR Master Mix (Applied Biosystem) in triplicates. qPCR and data collection were performed on a ViiA7 Real-Time PCR system (Invitrogen). Conditions used for qPCR were 95°C hold for 10 min, 40 cycles of 95°C for 10 s, 60°C for 15 s, and 72°C for 20 s. All quantitations were normalized to an endogenous control *ACTB*. The relative quantitation value for each target gene compared to the calibrator for that target is expressed as 2-(Ct-Cc) (Ct and Cc are the mean threshold cycle differences after normalizing to *ACTB*).

Tumorsphere cultures {#s4-13}
--------------------

Single cells were suspended in tumorsphere culture media containing 1% N2 supplement, 2% B27 supplement, 1% antibiotic-antimycotic, 20 ng/mL epidermal growth factor (Gibco, Carlsbad, CA), 20 ng/mL human bFGF-2 (Invitrogen), 10 ng/mL BMP4 (Sigma-Aldrich, St. Louis, MO), 10 ng/mL LIF (Sigma-Aldrich) and plated in six-well Ultra-Low Attachment Plates (Corning, Corning, NY).

siRNA transfection siRNA were purchased from Dharmacon (Lafayette, CO) and were transfected at 25 nM using Lipofectamine RNAiMAX Reagent (Invitrogen). siRNA sequences can be found in the Supplementary Material and methods.

Western blotting {#s4-14}
----------------

All lysates were boiled in 1x Laemmli sample buffer with β-mercaptoethanol for 5 min followed by electrophoresis on 4--20% Mini-PROTEAN TGX precast Tris-Glycine-SDS gels (Bio-Rad, Hercules, CA). Proteins were transferred to low-fluorescent PVDF (Bio-Rad) and incubated overnight in primary antibody at 1:1000 dilution. Blots were incubated in IRDye-conjugated secondary antibodies at room temperature for 1 hr and imaged/quantitated by an Odyssey CLx imaging system (Li-Cor, Lincoln, NE). For western blotting, HNF1A (clone GT4110) and KRAS (ab55391) from Abcam (Cambridge, MA), β-Actin (clone AC-74) from Sigma-Aldrich, Cadherin-17 (CDH17) from Proteintech (Rosemont, IL), β-Galactosidase from Promega (Madison, WI) and RAS^G12D^, CD44, EPCAM, DPP4, Cleaved Caspase-3 (D175), Cleaved Caspase-6 (D162), Cleaved Caspase-7 (D198), Cleaved Caspase-9 (D315), Cleaved Caspase-9 (D330), phospho-ERK1/2, phospho-AKT S473, OCT4A and GFP from Cell Signaling Technology (Danvers, MA). For flow cytometry, mouse anti-human EPCAM (CD326) clone HEA-125 was purchased from Miltenyi Biotec (San Diego, CA). Mouse anti-human CD44 clone G44-26, CD24 clone ML5 and APC-Cy7 Streptavidin were purchased from BD Biosciences (San Jose, CA). Biotinylated mouse anti-mouse H-2Kd/H-2Dd clone 34-1-2S was purchased from SouthernBiotech (Birmingham, AL).

Reporter assays {#s4-15}
---------------

For the Cypridina luciferase construct containing the full-length canonical OCT4 promoter, a 3.9-kbp insert was excised from phOct4-EGFP ([@bib14]) by XhoI and BamHI digestion, followed by ligation into pCLuc-Basic2 (New England Biolabs). phOct4-EGFP was a gift from Wei Cui (Addgene plasmid \# 38776). For the POU5F1/OCT4 LTR construct, a 1.7-kbp insert was amplified from NY5 genomic DNA with the following primers: 5'-ATCTTGGAATTCTGGGCACTCAGTTTATTGTTAGG-3' and 5'-GGTGGCGGATCCTGTGTTAATCCTCCTCGGGG-3'. The insert was digested with EcoRI and BamHI and cloned into pCLuc-Basic2. Cypridina luciferase constructs were co-transfected with Lipofectamine 2000 (Invitrogen) into 293FT cells with either LacZ or HNF1A lentiviral expression plasmids and the internal control plasmid pTK-GDLuc, a variant of pTK-GLuc (New England Biolabs) in which the Gaussia luciferase coding region was replaced with the coding region for Gaussia-Dura (Millipore) in order to provide a more stable luciferase signal. Cypridina and Gaussia-Dura luciferase activities were measured in conditioned media 48 hr post-transfection with the BioLux Cypridina Luciferase and BioLux Gaussia Luciferase Assay Kits (New England Biolabs), respectively.

Chromatin immunoprecipitation sequencing (ChIP-seq) {#s4-16}
---------------------------------------------------

A confluent 15 cm culture plate of cells was used per immunoprecipitation. Cells were fixed with 1% formaldehyde for 10 min. Nuclei were collected and chromatin sheared to 1--10 nucleosomes using the SimpleChIP Plus Enzymatic Chromatin IP kit and protocol (Cell Signaling). HNF1A was immunoprecipitated with goat polyclonal antibody C-19 (Santa Cruz). Libraries from HNF1A-immunoprecipitated chromatin and input chromatin was prepared by the University of Michigan Sequencing Core and sequenced on the Illumina HiSeq 4000.

Chromatin Immunoprecipitation-PCR {#s4-17}
---------------------------------

Chromatin was prepared as indicated for ChIP-seq and immunoprecitated with either normal goat IgG (R and D Systems) or anti-HNF1A (C-19, Santa Cruz Biotechnology) overnight using the SimpleChIP Plus Enzymatic Chromatin IP kit and protocol. Quantitative PCR was performed using immunoprecipitated DNA and 2% chromatin input DNA as described earlier for qRT-PCR using modified thermocycling conditions: 95°C hold for 10 min, 45 cycles of 95°C for 15 s and 60°C for 60 s. Percent Input for immunoprecipitated DNA was calculated using the formula 2% x 2^(Ct\ 2%\ Input\ Sample\ -\ Ct\ IP\ Sample)^. Primers for POU5F1/OCT4 regulatory regions were as follows: half-site \#1 (HS1) (5'-GTGAAATCTTTAGTGTTGTGAG-3' and 5'-CCAAGAAATGTAGCAGGACGAGCCCC-3'), half-site \#2 (HS2) (5'-AACCTTTTACATGAGCAGGTTTG-3' and 5'-AATGGTGGAAAGAATTACATGG-3'), half-site \#3 (HS3) (5'-GGGCACTCAGTTTATTGTTAGG-3' and 5'-TTTCCTGTCACAGGGGTTTAGTG-3'), and distal enhancer (DE) (5'-GAGAGGCCGTCTTCTTGGCAGAC-3' and 5'-GTTCACTTCTCGGCCTTTAACTGCCC-3'). MYOD (primers 5'-AGACTGCCAGCACTTTGCTATC-3' and 5'-ATAGAAGTCGTCCGTTGTGGC-3') was used as a non-HNF1A target gene control.

Bromouridine labeling and sequencing (Bru-seq) {#s4-18}
----------------------------------------------

Nascent RNA labeling and sequencing (Bru-seq) was performed as previously described ([@bib52]). For each shRNA (LacZ2.1, HNF1A shRNA\#1, and \#2), two replicates were performed in each cell line (NY8 and NY15). Cells were incubated in media containing 2 mM bromouridine (Bru) (Aldrich) for 30 min at 37°C. Total RNA was isolated after lysis in Trizol and Bru-RNA was isolated using anti-BrdU antibodies conjugated to magnetic beads. Strand-specific libraries were made using the Illumina TruSeq kit and sequenced on the Illumina HiSeq 4000 platform at the University of Michigan Sequencing Core (Ann Arbor, MI). Genes were recognized as differentially expressed in both cell lines if the fold change after knockdown was greater than 1.5 (and FDR \< 0.1 in NY15) and the mean RPKM for a given comparison was greater than 0.25 in either HNF1A shRNA\#1 or shRNA\#2 per cell line.

ChIP-seq analysis {#s4-19}
-----------------

The HNF1A ChIP-seq experiment consisted of 2 replicates each of input and ChIP libraries from both NY8 and NY15 cells (eight libraries altogether). 52-base, single end reads were aligned to the human reference genome (hg19) using Bowtie v1.1.1 (with options: -n 3 k 1 m 1). Peaks were called using MACS v1.4.2 using the default options and input samples as controls. MACS peaks overlapping ENCODE blacklist regions (<https://www.encodeproject.org/annotations/ENCSR636HFF>) were removed. Peak counts were 5057 (NY15 rep1), 8616 \*NY15 rep2), 64603(NY8 rep1), and 13169 (NY8 rep2). Each peak was assigned to the closest expressed gene's transcription start site (TSS). Then, for each TSS, the distance to the nearest peak was measured. If the nearest associated peak was within ±5 kb of the TSS, it was considered proximal. In the absence of a proximal peak, the nearest associated peak within ±100 kb of the TSS was considered distal. A gene was recognized as having a proximal or distal peak if at least one replicate in both cell lines identified a proximal or distal peak. If a gene was found to have both proximal and distal peaks (usually due to differences between replicates), the gene was identified as distal if it had distal peaks in both replicates of both cell lines, otherwise it was identified as neither. Manipulation of genomic regions was performed using bedtools2 (v2.26.0).

Bru-seq analysis {#s4-20}
----------------

The HNF1A knockdown experiment used for Bru-seq consisted of a control shRNA and two different HNF1A-targeting shRNAs for each of NY8 and NY15 cells, and 2 replicates of each (12 samples altogether). 52-base, stranded, single end reads were aligned first to ribosomal DNA (U13369.1) using Bowtie v0.12.8 and the remaining reads aligned to the human reference genome (hg19) using TopHat v1.4.1. Differential gene expression analysis was performed using DESeq v1.24.0 (R v3.3.1). Gene annotation and counting was performed as previously described ([@bib51]). Differentially expressed genes were selected based on the following criteria: mean RPKM \>0.25 across samples, minimum gene length 300, absolute value of log2 fold-change \>0.58 (1.5 fold-change), adjusted p value\<0.1, and these requirements met for at least one HNF1A shRNA in both cell lines.

Data access {#s4-21}
-----------

All ChIP-seq and Bru-seq data from this study are available at the NCBI Gene Expression Omnibus (GEO; accession \# GSE108151).

Enhancer-related analysis {#s4-22}
-------------------------

Enhancer regions used in this study were taken from the ENCODE Combined Segmentation annotation (<http://hgdownload.soe.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeAwgSegmentation/>) ([@bib21]; [@bib12]; [@bib20]). Regions labeled 'E' (strong enhancers) were extracted from all six cell lines used in the Combined Segmentation analysis, then merged to create a set of general putative enhancer regions. The enhancer regions were then queried against peak coordinated from each list of ChIP-seq peaks (see [Supplemental file 2](#supp2){ref-type="supplementary-material"}). All genomic region manipulations were performed using bedtools2 (v.2.26.0).

Survival analysis {#s4-23}
-----------------

Gene expression and patient survival data for pancreatic adenocarcinoma were obtained through the Broad Institute TCGA Genome Data Analysis Center (PAAD cohort; 2016; Firehose stddata\_\_2016_01_28 run; Broad Institute of MIT and Harvard; doi:10.7908/C11G0KM9). Clinical metadata were obtained from both the Merge Clinical Level one and Clinical Pick Tier 1 Level four data sets. Gene expression values were obtained from the Level 3 RSEM genes (normalized) data set and log~10~-transformed prior to analysis (a constant of 1 added to preserve zeros). Samples identified as primary solid tumors and of non-neuroendocrine origin were used. Specifically, samples with the following values in the 'patient.histological_type_other' field were rejected: '82463 neuroendocrine carcinoma nos', 'moderately differentiated ductal adenocarcinoma 60% + neuroendocrine 40%', 'neuroendocrine', 'neuroendocrine carcinoma', and 'neuroendocrine carcinoma nos'. The background set of genes were defined as those with Bru-seq RPKM greater than 0.5 in at least one replicate of both NY8 and NY15 cells and which mapped to either gene symbol or entrez gene ID in the TCGA expression data. Cox proportional hazards survival models were created using the R package survival (v2.40--1). For permutation testing against a particular set of HNF1A-related genes, random sets of genes of the same size were selected from the background set and the percent of genes significantly associated with reduced or increased survival (using FDR thresholds of 0.1 and 0.25) were calculated. In order for the estimated error of the estimated p value to be less than 10% (at significant level α = 0.05), we set the number of permutations (N) to 10,000.

Other statistical analysis {#s4-24}
--------------------------

The following methods are specific to analysis of the data represented in [Figures 1](#fig1){ref-type="fig"}--[6](#fig6){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. Data are expressed as the mean ±SEM. Statistically significant differences between two groups was determined by the two-sided Student t-test for continuous data, while ANOVA was used for comparisons among multiple groups. Significance was defined as p\<0.05. GraphPad Prism six was used for these analyses.

Study approval {#s4-25}
--------------

All animal protocols were approved by University Committee for the Use and Care of Animals (UCUCA) at University of Michigan. The animal welfare assurance number for this study is A3114-01. Patient samples were collected under a protocol approved by the IRB at the The University of Michigan. All patients gave informed consent. The human assurance number for this study is FWA00004969.
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###### Cancer stem cell frequencies in PDA subpopulations.

Limiting dilution assay was performed with sorted NY15 cells injected subcutaneously in NOD/SCID mice. The resultant numbers of tumors/injection is tabulated with estimated cancer stem cell frequencies calculated by extreme limiting dilution analysis (ELDA).

10.7554/eLife.33947.031

###### Data for generating PDA subpopulation heatmap and HNF1A target gene data (Excel spreadsheet).

Contents of each worksheet are as follows: worksheet 1) notes for summary tables; worksheet 2) Primers for qPCR validation of CSC50 genes; worksheet 3) table includes values represented in the [Figure 1E](#fig1){ref-type="fig"} where values are fold changes relative to HL or LH, as indicated; worksheet 4) NY8 and NY15 Bru-seq data related to [Figure 7A](#fig7){ref-type="fig"}; worksheet 5) NY8 and NY15 ChIP-seq data related to [Figure 7B](#fig7){ref-type="fig"} with information regarding enhancer binding; worksheet 6) summary of selected genes in expression vs survival in TCGA PAAD tumors - related to [Figure 7E](#fig7){ref-type="fig"}, S9A, and S9B, worksheet 7) HNF1A-upregulated and -bound genes: association between gene expression and survival in TCGA PAAD tumors - related to [Figure 7E](#fig7){ref-type="fig"}; worksheet 8) HNF1A-upregulated genes: association between gene expression and survival in TCGA PAAD tumors - related to [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}; worksheet 9) HNF1A-downregulated genes: association between gene expression and survival in TCGA PAAD tumors - related to [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}; worksheet 10) TCGA donors used in survival analysis - related to [Figure 7E](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A and B](#fig7s1){ref-type="fig"}; worksheet 11) Overrepresented TF-binding motifs in cancer stem cell gene set (CSC50), oPOSSUM3 results - related to [Figure 1](#fig1){ref-type="fig"}; worksheet 12) predicted HNF1A targets - related to [Figure 1](#fig1){ref-type="fig"}; worksheet 13) overrepresented TF-binding motifs in HNF1A upregulated genes, oPOSSUM3 results - related to [Figure 7D](#fig7){ref-type="fig"}; worksheet 14) overrepresented TF-binding motifs in HNF1A downregulated genes, oPOSSUM3 results - related to [Figure 7D](#fig7){ref-type="fig"}; worksheet 15) predicted POU5F1 targets - related to [Figure 7D](#fig7){ref-type="fig"}; worksheet 16) HNF1A ChIP-seq peak enhancer overlap, NY15 replicate 1 (rep1) - related to [Figure 7B](#fig7){ref-type="fig"}; worksheet 17) A ChIP-seq peak enhancer overlap, NY15 replicate 2 (rep2) - related to [Figure 7B](#fig7){ref-type="fig"}; worksheet 18) HNF1A ChIP-seq peak enhancer overlap, NY8 replicate 1 (rep1) - related to [Figure 7B](#fig7){ref-type="fig"}; worksheet 19) HNF1A ChIP-seq peak enhancer overlap, NY8 replicate 2 (rep2) - related to [Figure 7B](#fig7){ref-type="fig"}.

10.7554/eLife.33947.032

Data availability {#s7}
-----------------

All data from this study is available without limitations (GSE108151).

The following dataset was generated:

Abel EGoto MMagnuson BAbraham SRamanathan NHotaling EAlaniz AAKumar-Sinha CDziubinski MLUrs SWang LShi JWaghray MLjungman MCrawford HCSimeone DM2018HNF1A is a Novel Oncogene and Central Regulator of Pancreatic Cancer Stem Cells<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108151>Publicly available at the NCBI Gene Expression Omnibus (accession no. GSE108151).

The following previously published dataset was used:

Broad Institute TCGA Genome Data Analysis Center2016Analysis-ready standardized TCGA data from Broad GDAC Firehose 2016_01_28 run<http://gdac.broadinstitute.org/runs/stddata__2016_01_28/>No restrictions; all data available without limitations
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Decision letter

White

Richard M

Reviewing Editor

Memorial Sloan Kettering Cancer Center

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"HNF1A is a Novel Oncogene and Central Regulator of Pancreatic Cancer Stem Cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kevin Struhl as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Francisco X Real (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this letter to clarify our concerns about this work.

In this manuscript, Abel et al. describe a function for HNF1A as a potential new marker of the pancreatic cancer stem cell, and provide evidence of its oncogenic behavior. They utilize a series of patient derived cell lines and in vitro assays to demonstrate its function. The authors also provide evidence that HNF1A promotes stemness features in PDA through regulation of POU5F1/OCT4. The paper presents interesting new data, providing evidence for the oncogenic role of HNF1A in pancreatic cancer including functions in enhancing tumor initiating cell activity. However, there are some very significant concerns about the inconsistencies of cell lines for given experiments, lack of statistical analyses, and the interpretation of whether HNF1A is truly a CSC marker vs. simply an oncogene. These concerns raise questions as to the robustness of the proposed model.

Major points:

1\) Inconsistency in which cell lines were used:

The study uses multiple cell lines (i.e. NY5, NY8, NY15, NY90). While it is useful to have multiple cell lines, in many cases, they seem to be chosen at random and mainly to support the authors hypothesis. The significantly weakens the study. Some examples of this include:

A\) In Figure 2A, there looks to be little to no expression of HNF1A in NY8 or NY15 and yet surprisingly in Figure 2B, they then do knockdowns in those cell lines which in the previous Western blot looked to barely have any expression. If NY8 has no HNF1A expression, then how did they statistically quantify the effect of knockdown?

B\) Using siRNA against HNF1A (Figure 2C), the authors have shown that HNF1A-depletion strongly attenuates the growth of primary PDA cells NY5, NY8 and NY15, and produces a more modest effect on NY90. The P2 population is also reduced following HNF1A-depletion in these lines (Figure 3A), but present no statistics to support this. The authors suggest that basal HNF1A levels may predict dependency, but it is not clear whether the NY90 line has lower HNF1A protein levels than the other lines. Also, it would seem that correlating HNF1A levels specifically in the P2 population with dependency would be more consistent with the authors proposed model that HNF1A has specific functions in this sub-population of cells. These questions could be clarified by associating response to HNF1A knockdown and expression in the P2 population and by adding additional lines to the analysis.

C\) In Figure 4, the authors again use the NY8 line, which shows essentially no HNF1A expression, yet that is the line they previously (in Figure 3E) used to support knockdown experiments and decreased tumorsphere formation. How do they explain this discrepancy?

D\) In Figure 1---figure supplement 1, they use NY8 for Figure 1---figure supplement 1C but then NY15 for Figure 1---figure supplement 1D. Similarly, for Figure 1---figure supplement 2, they use NY15 for Figure 1---figure supplement 2D, then unclear what they used for Figure 1---figure supplement 2E.

These inconsistencies make the manuscript difficult to follow. To address this, the authors need to provide consistent data across the cell lines for each assay they have done. If a particular cell line is not appropriate, they need to explain the rationale for choosing that particular line. Moreover, it is essential that they provide statistical analysis of each assay performed.

2\) HNF1A as a CSC marker versus an oncogene

It is clear from the data that HNF1A promotes the growth of PDAC cells, and thus is likely an important oncogene. However, what is less clear is whether this is truly a CSC marker versus just an oncogene promoting growth. In Figure 1C, it does not look like there is much enrichment for HNF1A in NY8 cells, and in fact the co-expression of CD44 appears lower in the P2 fraction. In Figure 1D, the DPP fraction, which they argue is a HNF1A target, does not appear especially enriched in the P2 population in the NY5 line. Along the same lines, in Figure 1---figure supplement 1, there does not appear to be any enrichment of HNF1A in the stem cell fraction in NY5 cells. In Figure 3E, couldn\'t the decreased tumorspheres simply be due to a lower rate of proliferation as seen in Figure 2? This does not seem to support a stem cell function as much as a proliferation function. In Figure 4C, the authors once again switch to NY15 cells for unclear reasons, but the bigger issue with Figure 4, however, is that this is not really arguing for a CSC function -- it is mainly arguing that HNF1A acts as a classical oncogene -- it leads to more colony formation (Figure 4F and 4G) and cooperates with KRAS (Figure 4H and 4I).

Along the same lines, in Figure 5, the authors use mouse xenografts to argue that HNF1A is a CSC marker with knockdown studies. But the assays they did in Figure 5A-C really just argues it is an oncogene. To show stem cell function, they would need to do serial transplantation and limiting dilution analysis. I am not sure exactly what the data in Figure 5C is supposed to show, since the subcutaneous tumors are not very physiologically relevant yet this is where they show the depletion of the EPCAM/CD44/CD24 population -- why wasn\'t this done in the pancreatic tumors instead? Also, in Figure 5D, there does not appear to be much knockdown in HNF1A\#2, so why do they then see this quantification in NY5 cells in Figure 5E? In Figure 6D, the authors present data that knockdown of either HNF1A or OCT4 decreases tumorsphere, but along the same lines as previously noted, are these cells just sicker and/or not proliferating as well? This is especially true for the knockdown of OCT4 -- how does this affect growth or apoptosis? The photo shown in Figure 6G would suggest that the OCT4 knockdown cells are not very healthy. One way of addressing this issue is via the use of inducible shRNAs and/or cDNA rescue, to show that you can discern the growth inhibition effects versus just sick cells.

3\) HNF1A/OCT4

It is important to show the data on the ChIP-PCR of HNF1A at the OCT4 promoter (mentioned in the Discussion) and provide some more detail about the putative elements involved in regulation. It would be desirable to show promoter-reporter assays at this locus to demonstrate this is really important in its function.

4\) Bioinformatics issues

A more detailed description of the ChIP-seq methods (description of experiments, replicates, number of peaks, concordance of replicates, etc.) and analysis of the results of these experiments. In addition, a more detailed description of the merged results of RNA-Seq and ChIP-seq would be valuable, including motif analysis of the promoter of genes whose expression was deregulated upon HNF1A knockdown (is OCT4 motif enriched? Any other candidates? Are OCT4 targets enriched as well among the deregulated genes?). A more detailed study of the possible role of distant regulatory sites through the analysis of ENCODE data for enhancer activity would be also important to support the regulatory role on target genes.

Regarding the analysis of association with prognosis: were these analyses corrected for multiple testing? Were signatures better than individual genes? Could the data be validated in the ICGC series? These are relevant questions that should be readily addressable.

Can the authors clarify whether OCT4 expression correlates with HNF1A expression across PDA cell lines and tumors and whether OCT4 is enriched in the P2 population?

10.7554/eLife.33947.042

Author response

> Major points:
>
> 1\) Inconsistency in which cell lines were used:
>
> The study uses multiple cell lines (i.e. NY5, NY8, NY15, NY90). While it is useful to have multiple cell lines, in many cases, they seem to be chosen at random and mainly to support the authors hypothesis. The significantly weakens the study. Some examples of this include:
>
> A\) In Figure 2A, there looks to be little to no expression of HNF1A in NY8 or NY15 and yet surprisingly in Figure 2B, they then do knockdowns in those cell lines which in the previous Western blot looked to barely have any expression. If NY8 has no HNF1A expression, then how did they statistically quantify the effect of knockdown?
>
> B\) Using siRNA against HNF1A (Figure 2C), the authors have shown that HNF1A-depletion strongly attenuates the growth of primary PDA cells NY5, NY8 and NY15, and produces a more modest effect on NY90. The P2 population is also reduced following HNF1A-depletion in these lines (Figure 3A), but present no statistics to support this. The authors suggest that basal HNF1A levels may predict dependency, but it is not clear whether the NY90 line has lower HNF1A protein levels than the other lines. Also, it would seem that correlating HNF1A levels specifically in the P2 population with dependency would be more consistent with the authors proposed model that HNF1A has specific functions in this sub-population of cells. These questions could be clarified by associating response to HNF1A knockdown and expression in the P2 population and by adding additional lines to the analysis.

We agree that the levels of HNF1A in the cell lines used might have been confusing in the original submission, and have re-configured the figures as well as added numerous additional new western blots to demonstrate expression data in a more robust way. We have focused our studies on 3 low-passage primary human PDA lines (NY5, NY8, NY15), and have used them throughout the manuscript to maintain consistency. Additionally, quantitation of Western blots has been added throughout the manuscript to help with interpretation, including that HNF1A protein is elevated in the P2 (EPCAM+/CD44+) subpopulation and that HNF1A expression is tightly linked to PCSC marker expression.

> C\) In Figure 4, the authors again use the NY8 line, which shows essentially no HNF1A expression, yet that is the line they previously (in Figure 3E) used to support knockdown experiments and decreased tumorsphere formation. How do they explain this discrepancy?

We have included clear data by western blotting (Figure 2A) and mRNA expression (Figure 2---figure supplement 1A) that demonstrates expression of HNF1A in NY8 cells. Further, we have demonstrated that both knockdown (Figure 3C-E), and overexpression of HNF1A (Figure 4B and 4E) is significantly correlated with tumorsphere formation.

> D\) In Figure 1---figure supplement 1, they use NY8 for Figure 1---figure supplement 1C but then NY15 for Figure 1---figure supplement 1D. Similarly, for Figure 1---figure supplement 2, they use NY15 for Figure 1---figure supplement 2D, then unclear what they used for Figure 1---figure supplement 2E.
>
> These inconsistencies make the manuscript difficult to follow. To address this, the authors need to provide consistent data across the cell lines for each assay they have done. If a particular cell line is not appropriate, they need to explain the rationale for choosing that particular line. Moreover, it is essential that they provide statistical analysis of each assay performed.

As stated above, we have streamlined our use of consistent primary PDA cell lines throughout the manuscript. In addition, we have provided statistical analysis for each assay performed throughout the manuscript.

> 2\) HNF1A as a CSC marker versus an oncogene
>
> It is clear from the data that HNF1A promotes the growth of PDAC cells, and thus is likely an important oncogene. However, what is less clear is whether this is truly a CSC marker versus just an oncogene promoting growth. In Figure 1C, it does not look like there is much enrichment for HNF1A in NY8 cells, and in fact the co-expression of CD44 appears lower in the P2 fraction.

We provide clear data throughout the manuscript that HNF1A is upregulated in NY8 cells in the P2 population and that this population possesses CSC functionality, including self-renewal, expression of cancer stem cell markers, sphere formation, and increased tumor initiation. In addition to the differentially expressed HNF1A mRNA quantitated in Figure 1C, quantitation of HNF1A protein levels from sorted NY5, NY8, and NY15 has been added to clarify the association of HNF1A expression and the P2 subpopulation. Cells in the P2 subpopulation express medium levels of EPCAM and CD44 when compared to the P1 and P3 (Figure 1---figure supplement 1B), and as such we have re-described the P2 cells as "CD44^Med^/EPCAM^Med^."

> In Figure 1D, the DPP fraction, which they argue is a HNF1A target, does not appear especially enriched in the P2 population in the NY5 line. Along the same lines, in Figure 1---figure supplement 1, there does not appear to be any enrichment of HNF1A in the stem cell fraction in NY5 cells.

To address the concerns regarding expression of DPP4, an additional known transcriptional target of HNF1A, we have included quantitated Western blots to support that DPP4 is most highly expressed in the P2 subpopulation (Figure 1---figure supplement 1B), similar to HNF1A and CDH17.

> In Figure 3E, couldn\'t the decreased tumorspheres simply be due to a lower rate of proliferation as seen in Figure 2? This does not seem to support a stem cell function as much as a proliferation function.

Tumorsphere formation is a well-established in vitro measure of CSC function. In Figures 1C and 1D we show that the P1 and P3 subpopulations of PDA cells, which have reduced HNF1A expression, are also markedly reduced in their ability to form tumorspheres without any additional perturbation (i.e. HNF1A knockdown). Additionally, HNF1A expression is increased in tumorspheres (Figure 1---figure supplement 2). In Figures 3 and 4, we demonstrate that altering HNF1A expression in PDA cells results in increased or decreased tumorsphere forming activity in a manner that corresponds to HNF1A expression levels. Collectively, these data support a tight association between HNF1A levels and tumorsphere formation. Lastly, Figure 6 and Figure 6---figure supplement 2 demonstrate that OCT4 is the mechanistic link between HNF1A and sphere formation, and importantly that knockdown of OCT4 does not affect cell cycle or apoptosis in PDA cells (Figure 6---figure supplement 2).

> In Figure 4C the authors once again switch to NY15 cells for unclear reasons, but the bigger issue with Figure 4, however, is that this is not really arguing for a CSC function -- it is mainly arguing that HNF1A acts as a classical oncogene -- it leads to more colony formation (Figure 4F and 4G) and cooperates with KRAS (Figure 4H and 4I).

The updated Figure 4 now contains overexpression of HNF1A in three primary PDA models (NY8, NY15, and NY53) throughout the figure. The purpose of using these cells, which was to test whether overexpression of HNF1A could further promote CSC-marker expression and tumorsphere formation in PDA cells with varying endogenous levels of HNF1A, is now clearly stated in the Results. The results show that HNF1A overexpression increases both CSC-marker expression and tumorsphere formation, consistent with the knockdown data in Figure 3.

We agree with the reviewer that HNF1A is capable of acting as an oncogene and have chosen this suggested designation throughout the revised manuscript, including the title. That said, our data also support that part of its oncogenic activity is through its regulation of PCSC function like other oncogenes we and others have identified, such as NOTCH (Abel et al., 2014), BMI1 (Proctor et al., 2013), c-MET (Li et al., 2011a; Li et al., 2011b), and NRAS (Li et al., 2013).

> Along the same lines, in Figure 5, the authors use mouse xenografts to argue that HNF1A is a CSC marker with knockdown studies. But the assays they did in Figure 5A-C really just argues it is an oncogene. To show stem cell function, they would need to do serial transplantation and limiting dilution analysis.

We agree with the reviewer that limiting dilution analysis is a valuable assay to assess CSC function. Due to the time constraints imposed for revision, this assay was not feasible. However, to acknowledge these concerns, we have adopted the language that HNF1A acts as an oncogene that regulates PSCS properties. To support the latter claim, we demonstrate increased expression of HNF1A in a CSC population capable of self-renewal and generation of the diverse progeny observed in the original tumor sample (Figure 1 and Figure 1---figure supplement 1), enhanced expression of HNF1A in tumor-sphere forming conditions (Figure 1---figure supplement 2), the ability of HNF1A to regulation expression of CSC markers (Figures 3 and 4; and related figure supplements) and enhancement of tumor growth (Figure 5 and Figure 5---figure supplement 1). In the revised manuscript, we also provide new data (Figure 6; Figures 6---figure supplements 1 and 2) that HNF1A is linked to the stem cell protein OCT4 as a critical downstream mediator of HNF1A function, through its direct interaction of its distal promoter.

We conclude that HNF1A joins a group of oncoproteins that regulate cancer stem cell activity (e.g. c-MET, NOTCH, BMI1, etc.).

> I am not sure exactly what the data in Figure 5C is supposed to show, since the subq tumors are not very physiologically relevant yet this is where they show the depletion of the EPCAM/CD44/CD24 population -- why wasn\'t this done in the pancreatic tumors instead?

We have previously shown that assays assessing PCSC function are similar in head-to-head orthotopic and subcutaneous implantation experiments (Li et al., 2007; Li et al., 2011a), demonstrating that the subcutaneous model is equally effective as the orthotopic model in defining PCSC function. Consistent with our previous findings, both orthotopic and subcutaneous tumor assays had similar results with regards to tumor growth in this study. Additionally, orthotopic tumors were labeled with GFP-luciferase, which prevented use of flow cytometry to quantitate PCSCs. Unlabeled cells were used for the subcutaneous tumor models, which allowed for PCSC staining. The results of these two experiments are complementary.

> Also, in Figure 5D there does not appear to be much knockdown in HNF1A\#2, so why do they then see this quantification in NY5 cells in Figure 5E?

We have provided a clearer representative image in Figure 5D to demonstrate that the HNF1A shRNA\#2 provide significant knockdown effects, and the cumulative results in Figure 5E show the effectiveness of HNF1A knockdown in depleting the CSC population in vivo(p\<0.001 for both shRNAs).

> In Figure 6D, the authors present data that knockdown of either HNF1A or OCT4 decreases tumorsphere, but along the same lines as previously noted, are these cells just sicker and/or not proliferating as well? This is especially true for the knockdown of OCT4 -- how does this affect growth or apoptosis? The photo shown in Figure 6G would suggest that the OCT4 knockdown cells are not very healthy. One way of addressing this issue is via the use of inducible shRNAs and/or cDNA rescue, to show that you can discern the growth inhibition effects versus just sick cells.

We have added new data to show that PDA cells are responsive to OCT4 knockdown in tumorsphere assays (Figure 6E and 6I), and did not show a significant change in cell cycle (propidium iodide staining) or apoptosis (annexin V staining) following knockdown of OCT4 (Figure 6---figure supplements 2A and 2B). These data indicate that knockdown of OCT4 is not preventing tumorsphere formation via cell death or cytostasis in PDA cells. Additionally, OCT4 is a well-established stem cell regulator (Okita et al., 2007; Takahashi and Yamanaka, 2006), and has been shown to play a role in cancer stem cells as well (Lu et al., 2013; Kumar et al., 2012; Nishi et al., 2013). Our data is consistent with the canonical role of OCT4 as a key regulator of stemness, both in normal cells and in cancer.

> 3\) HNF1A/OCT4
>
> It is important to show the data on the ChIP-PCR of HNF1A at the OCT4 promoter (mentioned in the Discussion) and provide some more detail about the putative elements involved in regulation. It would be desirable to show promoter-reporter assays at this locus to demonstrate this is really important in its function.

We appreciate this comment and have in fact done several additional experiments to support that HNF1A binds to the OCT4 promoter. Using ChIP-PCR, we were able to demonstrate enrichment of the OCT4 LTR promoter (Malakootian et al., 2017) (Figure 6---figure supplement 1C), previously mentioned in the Discussion. Additionally, we were able to demonstrate that this region functions as an HNF1A-responsive promoter in promoter-reporter assays (Figure 6---figure supplement 1D). These data support a direct regulatory interaction between HNF1A and the OCT4 LTR promoter.

> 4\) Bioinformatics issues
>
> A more detailed description of the ChIP-seq methods (description of experiments, replicates, number of peaks, concordance of replicates, etc.) and analysis of the results of these experiments.

We have added more detail about the Bru-seq/ChIP-seq in the Results and Materials and methods section.

> In addition, a more detailed description of the merged results of RNA-Seq and ChIP-seq would be valuable, including motif analysis of the promoter of genes whose expression was deregulated upon HNF1A knockdown (is OCT4 motif enriched? Any other candidates? Are OCT4 targets enriched as well among the deregulated genes?).

We used an overrepresentation analysis to find TF binding sites in promoters of HNF1A-responsive genes (see Figure 7D and Supplementary file 2 for the complete results). POU5F1 (OCT4) was the most highly ranked predicted TF for the HNF1A-repressed genes. OCT4 targets were indeed found among the HNF1A-repressed genes (now included in the Results).

> A more detailed study of the possible role of distant regulatory sites through the analysis of ENCODE data for enhancer activity would be also important to support the regulatory role on target genes.

Using ENCODE enhancer data from 6 merged cell lines we examined ChIP-seq peak overlap with identified enhancer regions. For the HNF1A-bound genes represented in Figure 7B, we indicated the fraction of genes with enhancer-overlapping peaks. We have also added a list of merged enhancer regions and a list of peaks indicating overlap or non-overlap in the Supplementary file 2. 72.7% of HNF1A-bound genes had peaks overlapping in at least one of these putative enhancer regions, suggesting that HNF1A has significant interaction with regulatory regions.

> Regarding the analysis of association with prognosis: were these analyses corrected for multiple testing?

The original analysis presented did not apply p value adjustment before selecting significant genes. In the process of revisiting this issue, we decided to use a Cox PH model for survival, since gene expression is a continuous variable and is thus well suited, instead of the median-stratification model we used previously. We present the revised analysis showing both the FDR 0.1 and 0.25 as thresholds for gene selection (Figure 7, Figure 7---figure supplement 1). The permutation tests at the different thresholds agree, suggesting the selection threshold is not critical.

> Were signatures better than individual genes?

We have added additional analysis of the TCGA dataset. Permutation tests showed that HNF1A-activated genes were significantly associated with poorer outcomes versus randomly selected genes (insets, Figure 7E and Figure 7---figure supplement 1A; see Materials and methods for details). These findings further support the oncogenic role for HNF1A in PDA as a direct regulator of a set of genes associated with poor patient survival.

> Could the data be validated in the ICGC series? These are relevant questions that should be readily addressable.

As suggested, we applied our survival analysis to the ICGC data set (PACA-AU cohort). For HNF1A activated/bound genes, 7 overlapping genes were identified in this manner using both the TCGA and ICGC analyses. The ICGC result contrasts the TCGA result in that genes associated with increased survival were also identified, whereas in the TCGA result, no such genes were found ([Author response image 1](#respfig1){ref-type="fig"}). A likely source of this discrepancy is a general disagreement among the single-gene survival models. At p \< 0.01 (highly significant) very few background genes overlapped between the two datasets ([Author response image 2](#respfig2){ref-type="fig"}).

It is possible that the underlying difference between the ICGC and TCGA datasets is the relatively high tumor cellularity requirement for ICGC samples (at least 40%) (Waddell et al., 2015; Bailey et al., 2016). By contrast, TCGA also utilized samples with low tumor cellularity (Network, 2017), a common hallmark of PDA. While it is unclear that sample selection criterion accounts for this disparity between datasets, we do however believe that the usage of a more representative collection of samples by the TCGA justifies our reliance on the dataset in our study. We are receptive to alternative solutions should the reviewer disagree.

![Comparison of TCGA and ICGC survival analyses.](elife-33947-resp-fig1){#respfig1}

![Comparison of TCGA and ICGC background gene concordance.\
Overlap of all genes is on the left, "UP" refers to increased survival genes, "DN" to reduced survival genes.](elife-33947-resp-fig2){#respfig2}

> Can the authors clarify whether OCT4 expression correlates with HNF1A expression across PDA cell lines and tumors and whether OCT4 is enriched in the P2 population?

Using qRT-PCR analysis to quantitate both HNF1A and POU5F1 (OCT4) mRNA levels in 22 primary PDA cell lines as well as HPNE and HPDE cells, we found a significant positive correlation (r=0.5189, p=0.0094, Figure 6C) between the mRNA levels of both genes. Additionally, we also found a positive correlation (r=0.4064, p=8.9x10^-8^, [Author response image 3](#respfig3){ref-type="fig"}) between HNF1A and POU5F1 mRNA levels in patient data from TCGA. We did not, however, observe a significant association between POU5F1 mRNA and any of the PDA subpopulations ([Author response image 3](#respfig3){ref-type="fig"}). This would suggest that factors other than HNF1A modulate the levels of POU5F1 mRNA in different PDA subpopulations.

![Correlation of HNF1A and POU5F1 expression.](elife-33947-resp-fig3){#respfig3}
